Introduction

The 2018 Top Management and Performance Challenges Facing HHS is an annual publication of the Department of Health and Human Services (HHS or the Department) Office of Inspector General (OIG). In this edition, OIG has identified 12 top management and performance challenges (TMCs) facing the Department as it strives to fulfill its mission “to enhance the health and well-being of all Americans, by providing for effective health and human services and by fostering sound, sustained advances in the sciences underlying medicine, public health, and social services.” These top challenges arise across HHS programs and cover critical HHS responsibilities that include delivering quality services and benefits, exercising sound fiscal management, safeguarding public health and safety, and enhancing cybersecurity. The Department should be mindful of these challenges and opportunities to address them as it undertakes its efforts to Reimagine HHS as part of the Federal Government’s comprehensive plan to reform Government.

HHS is responsible for a portfolio of more than $1 trillion, and its programs impact the lives of virtually all Americans. To identify the top 12 challenges, we synthesized our oversight, risk analysis, data analytics, and enforcement work. For each top challenge, we identify the key components, the Department’s progress in addressing the challenge, and what needs to be done. There are many cross-cutting issues that transcend all the TMCs. Examples include improper payments, the quality of services provided and care received by beneficiaries, promoting effective use of health IT, and combatting fraud. Each challenge also lists key OIG resources related to that challenge.

Additionally, OIG maintains a list of significant unimplemented OIG recommendations, including legislative recommendations, to address vulnerabilities. These recommendations are drawn from OIG’s audits and evaluations. OIG identifies the top unimplemented recommendations that, in OIG’s view, would most positively affect HHS programs in terms of cost savings, program effectiveness and efficiency, and public health and safety.¹ More information on OIG’s work, including the reports mentioned in this publication, are on our website at https://oig.hhs.gov.

# Table of Contents

Top Management and Performance Challenges Facing HHS

1. Preventing and Treating Opioid Misuse ................................................................. 1
2. Ensuring Program Integrity in Medicare Fee-for-Service and Effective Administration of Medicare ................................................................. 7
3. Ensuring Program Integrity and Effective Administration of Medicaid .......... 13
4. Ensuring Value and Integrity in Managed Care and Other Innovative Healthcare Payment and Service Delivery Models ............................................. 17
5. Protecting the Health and Safety of Vulnerable Populations ......... 21
6. Improving Financial and Administrative Management and Reducing Improper Payments ................................................................. 28
7. Protecting the Integrity of HHS Grants ................................................................. 33
8. Ensuring the Safety of Food, Drugs, and Medical Devices ...... 37
9. Ensuring Quality and Integrity in Programs Serving American Indian/Alaska Native Populations ................................................................. 41
10. Protecting HHS Data, Systems, and Beneficiaries from Cybersecurity Threats .... 45
11. Ensuring that HHS Prescription Drug Programs Work as Intended ............. 48
12. Ensuring Effective Preparation and Response to Public Health Emergencies .... 53
1. Preventing and Treating Opioid Misuse

**Why This Is a Challenge**
In 2017, the President declared the opioid crisis a nationwide public health emergency. Some analysts estimate that up to 6 million Americans could have opioid use disorder. In 2017, it is estimated that more than 49,000 opioid-related overdose deaths occurred in the United States (U.S.), an average of 134 deaths per day.

Across multiple agencies and programs, HHS has many opportunities to help curb the opioid epidemic. Medicare provides prescription drug coverage for 45 million Part D beneficiaries and Medicaid for 67 million beneficiaries. The Indian Health Service (IHS) provides care for 2.2 million beneficiaries. The U.S. Food and Drug Administration (FDA) oversees the approval and safe use of prescription drugs. HHS agencies also conduct research and award grants to support healthcare providers, researchers, and States in their efforts to combat the epidemic.

**Reducing inappropriate prescribing and misuse of opioids**

**Key Components of the Challenge**
- Reducing inappropriate prescribing and misuse of opioids
- Combating fraud and diversion of prescription opioids and potentiator drugs
- Ensuring access to appropriate treatment for opioid use disorder
- Ensuring that funding for prevention and treatment is used appropriately

OIG found that almost 460,000 Medicare Part D beneficiaries received high amounts of opioids in 2017. In addition, almost 300 prescribers engaged in questionable opioid prescribing. These prescribers ordered opioids for the highest number of beneficiaries at serious risk of opioid misuse or overdose. This does not include prescribing for beneficiaries who have cancer or were in hospice care.

Beneficiaries at serious risk include those who received extreme amounts of opioids and those who appeared to be doctor shopping (i.e., receiving high amounts of opioids from multiple prescribers and multiple pharmacies).

Medicaid beneficiaries may be especially vulnerable to opioid misuse because they are more likely than nonbeneficiaries to have chronic conditions and comorbidities that require pain relief, especially those who qualify because of a disability. In 2016, Medicaid covered nearly 4 in 10 nonelderly adults with opioid addiction, while only 15 percent of the nonelderly adult population is covered by Medicaid. OIG found that one in six Medicaid beneficiaries in Ohio received an opioid in a 1-year period, and nearly 5,000 Ohio beneficiaries received high amounts of opioids.

Health disparities and inadequate healthcare services for American Indians and Alaska Natives (AI/AN) have been a subject of concern for the Federal Government for almost a century. AI/AN had the second highest rate of opioid overdose deaths in 2015 and 2016. IHS is responsible for implementing appropriate controls within its pharmacies to reduce and detect diversion of opioids. OIG has found

---


3 Extreme is defined as an average daily morphine equivalent dose greater than 240 mg for 12 months.

vulnerabilities at some IHS pharmacies that could put patient safety at risk and allow inappropriate prescribing of opioids.

**Progress in Addressing the Challenge**
The Department has engaged several Operating Divisions in efforts to address inappropriate prescribing and misuse of opioids. Monitoring of prescription drug claims is one tool to prevent inappropriate prescribing and misuse of opioids. The Centers for Medicare & Medicaid Services (CMS) has taken steps to help reduce misuse of opioids, including strengthening drug utilization reviews, a tool that assists Medicare Part D sponsors in preventing misuse. In October 2017, States and CMS convened to discuss vulnerabilities, mitigation strategies, challenges, and barriers related to State Medicaid opioid efforts. In June 2018, CMS continued to provide guidance to help States combat the opioid crisis in Medicaid, including information on effective practices to identify substance use disorders covered under Medicaid. The Centers for Disease Control and Prevention (CDC) has awarded funding to States to improve prescription drug monitoring programs (PDMPs), which are statewide databases that track prescriptions. In 2016, IHS implemented a policy requiring prescribers to utilize PDMP data to identify at-risk patients. PDMPs assist in identifying prescribers at risk of inappropriate prescribing and allow authorized users to identify patients who are obtaining opioids from multiple providers.

Education of providers, the industry, and beneficiaries on appropriate prescribing and pain management also plays a role in the prevention of opioid abuse. For example, IHS changed its policy regarding opioid prescribing to align with CDC guidelines for prescribing opioids for chronic pain. Furthermore, FDA is encouraging appropriate prescribing of opioid analgesics through the Risk Evaluation and Mitigation Strategy (REMS) program for opioid analgesics. The Opioid Analgesic REMS, approved on September 18, 2018, includes as the primary component that training be made available to all healthcare providers (HCPs) who are involved in the management of patients with pain, including nurses and pharmacists. To meet this requirement, drug manufacturers with approved opioid analgesics will provide unrestricted grants to accredited continuing education providers for the development of education courses for HCPs based on the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain (Blueprint). It is expected that continuing education based upon the new Blueprint will be available to healthcare providers by March 2019.  

To prevent misuse of opioids, HHS has educated providers and the public about alternative options for pain management. IHS established a National Committee on Heroin, Opioids, and Pain Efforts to promote appropriate and effective pain management, reduce overdose deaths, and improve access to treatment.

When opioid use becomes addiction, information on treatment is important. In 2017, HHS launched its 5-Point Opioid Strategy to improve access to treatment, improve data, promote better pain management, increase the availability of overdose-reversing drugs, and increase research on pain and addiction. In April 2018, NIH launched the Helping to End Addiction Long-term (HEAL) initiative to improve treatments for opioid misuse and addiction.

**What Needs To Be Done**

- HHS agencies should monitor and assess the effectiveness of their ongoing efforts.
- OIG recommends that CMS continue to develop prescriber educational tools outlining how to appropriately prescribe opioids when medically necessary. As part of this education, CMS should

---

engage with those providers who may be prescribing inappropriately, to make sure they have the tools to prescribe appropriately.

- States and IHS should continue efforts to implement and encourage the use of PDMPs. Routinely checking States’ PDMPs is an important step toward improving how opioids are prescribed and reducing opioid misuse, abuse, and overdose.
- Medicaid beneficiary data should be shared among States and with HHS so that potential patient harm is identified. Beneficiaries can cross State boundaries to obtain opioids and thereby miss being flagged by a State’s PDMP for potentially excessive opioid use.

### Combating fraud and diversion of prescription opioids and potentiator drugs

**Key Components of the Challenge**

Several years ago, OIG detected—and began taking action to address—a rise in fraud schemes involving opioids, as well as associated potentiator drugs. Opioid fraud encompasses a broad range of criminal activity from prescription drug diversion to addiction treatment schemes.

OIG investigations of opioid drug diversion, which is the redirection of legitimate drugs for illegitimate purposes, are on the rise. Diverted opioid drugs are at high risk to be used inappropriately and create significant harm, including increasing the risk of overdose. Also at risk for diversion are potentiator drugs, which are drugs that exaggerate euphoria when combined with opioids and escalate the potential for misuse. Prescription opioids indicated to treat pain and those indicated to treat opioid use disorder (particularly, buprenorphine) are also at high risk of diversion.

**Progress in Addressing the Challenge**

OIG, along with State and Federal law enforcement partners, participated in an unprecedented fraud takedown to combat healthcare fraud and the opioid epidemic in June 2018. More than 160 defendants were charged with participating in Medicare and Medicaid fraud schemes related to opioids or treatment for opioid use disorders. These defendants included 32 doctors who were charged for their roles in prescribing and distributing opioids and other dangerous narcotics.

To support public and private sector partners in combatting the opioid crisis, OIG released a toolkit providing detailed steps for using prescription drug claims data to analyze patients’ opioid levels and identify certain patients who are at risk of opioid misuse or overdose. Partners such as Medicare Part D plan sponsors, private health plans, and State Medicaid Fraud Control Units (MFCUs) can now analyze their own prescription drug claims data using the methodology OIG developed on the basis of its work on opioids.

CMS finalized regulations to guide Medicare plans to implement “lock-in” authority. Lock-in allows Medicare plans to better manage at-risk beneficiaries’ medication regimens by limiting their access to opioids to certain prescribers and pharmacies. CMS has issued Quarterly Reports of Part D outlier prescribers of opioids and other prescription drugs; these prescribers have a high potential for abuse. Additionally, IHS implemented system and physical controls at certain IHS hospitals to help ensure opioids are secure. These controls help to ensure prescription drugs and pharmacy information are protected, thus lessening the chance that drugs could be illegally diverted.
### What Needs To Be Done

- HHS agencies should improve efforts to identify and investigate potential fraud and abuse. For instance, CMS should collect comprehensive data from Medicare Part D plan sponsors.
- CMS should ensure that national Medicaid data are sufficient to detect suspected fraud or abuse.
- CMS and States should follow up on prescribers with questionable prescribing patterns to ensure that Medicare Part D and Medicaid are not paying for unnecessary drugs that are being diverted for resale or recreational use.
- IHS should improve controls at entry points to sensitive areas of its hospitals to protect its pharmacy inventory from unauthorized access.
- IHS should continue to strengthen its systems controls to ensure unauthorized individuals cannot gain access to sensitive patient information.

### Ensuring access to appropriate treatment for opioid use disorder

#### Key Components of the Challenge
Given the scope of the epidemic, access to high quality treatment of opioid use disorder is a priority and a challenge. Only 10 percent of people who need treatment for substance use disorder receive that treatment. Rates of drug overdose deaths are rising in rural areas, surpassing rates in urban areas. At the same time, rural areas are often more limited in their access to treatment. The Government Accountability Office found that the regulatory restrictions placed on providers, such as patient limits, and the stigmas related to drug addiction and medication assisted treatment (MAT) are barriers that may limit providers’ participation in treatment.

Increasing access to MAT and programs must be balanced with the increased risk for fraud involving addiction treatment schemes. Fraud committed by providers of treatment for opioid use disorder is a concern as it both diverts funds and puts beneficiaries at risk.

#### Progress in Addressing the Challenge
HHS has been implementing provisions of the Comprehensive Addiction and Recovery Act of 2016. This includes allowing a temporary expansion of prescribing authority for MAT to other healthcare providers beyond physicians, including nurse practitioners and physician assistants.

HHS agencies have taken steps to expand MAT treatment options and access. The Substance Abuse and Mental Health Services Administration (SAMHSA) reviewed the use of three medications (methadone, naltrexone, and buprenorphine) to treat opioid use disorders. In addition, in 2018, the Health Resources and Services Administration (HRSA) made $350 million available to expand access to treatment, including MAT, at community health centers. The number of health center clinicians providing MAT increased from 1,700 in 2016 to nearly 3,000 in 2017. Further, FDA issued scientific recommendations.

---


to encourage the development of MAT drugs.\textsuperscript{9} FDA also approved the first generic versions of Suboxone, which may increase access to treatment of opioid dependence.\textsuperscript{10}

Additionally, CMS has allowed States to design demonstration projects that increase access to a continuum of treatment services for opioid use disorders. It also allows State Medicaid agencies to reimburse for treatment at inpatient facilities with more than 16 beds which are otherwise prohibited by current exclusions.

**What Needs To Be Done**

- CMS and SAMHSA should monitor the success of their efforts to increase access to MAT.
- SAMHSA must adequately oversee the waiver process for physicians to prescribe or dispense specific narcotic medications in settings other than opioid treatment programs.
- CMS should continue to develop reimbursement policies that foster the development of services to ensure that treatment resources and the number of qualified providers are sufficient to provide beneficiaries ready access where and when needed.

**Ensuring that funding for prevention and treatment is used appropriately**

**Key Components of the Challenge**

To build upon the work started under the 21st Century Cures Act (Cures Act), HHS was appropriated more than $1 billion in new funding to combat the opioid epidemic and address serious mental illness.

While Medicare and Medicaid pay the biggest share of Federal payments for treatment, SAMHSA is awarding approximately $930 million in fiscal year (FY) 2018 State Opioid Response grants and awarded approximately $484 million in Opioid State Targeted Response grants in FY 2017. Ensuring these funds are used appropriately is a top priority. As with any Federal program, significant increases in funding and subsequent disbursement raises the risk for waste, abuse, and inefficient use (see TMC #7 for more information on challenges specific to HHS grants).

**Progress in Addressing the Challenge**

In the Agency Priority Goal Action Plan to Reduce Opioid Morbidity and Mortality, the Department publishes quarterly updates on its progress on HHS-funded projects to combat the opioid crisis. For example, HRSA reported that it collects quarterly progress-report data from grantees who received funding in 2017 to increase access to substance abuse and mental health services, the Rural Health Opioid Program, and the Substance Abuse Treatment Telehealth Network Grant Program.

NIH ensures its funded opioid research adheres to NIH Grants Compliance and Oversight policies. NIH uses proactive compliance site visits to assess institutional understanding of Federal policies and regulations, minimize or eliminate areas of noncompliance, and nurture partnerships between NIH and its recipient institutions. NIH also uses targeted site visits to focus on recipients’ compliance with Financial Conflict of Interest regulations.


\textsuperscript{10} FDA, “FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence,” June 14, 2018. Accessed at: [https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm610807.htm](https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm610807.htm).
CMS conducts State Program Integrity desk reviews of State Medicaid activities to assist in combatting the opioid epidemic. In FY 2018, CMS began conducting opioid desk reviews to gather information related to certain States’ current programs, delivery systems, policies and/or noteworthy practices in response to the opioid crisis.

**What Needs To Be Done**

- OIG will monitor and review grantees’ use of Federal funds for opioid abuse prevention and treatment programs, and, as appropriate, use its criminal, civil, and administrative enforcement authorities to prevent fraud.
- SAMHSA and other HHS operating divisions should identify and refer cases to OIG involving grantee fraud or misuse of Federal funds for opioid abuse prevention and treatment programs.

**Key OIG resources**

- *Opioids in Medicare Part D: Concerns about Extreme Use and Questionable Prescribing (OEI-02-17-00250)*, July 2017.
- *Toolkit: Using Data Analysis to Calculate Opioid Levels and Identify Patients at Risk of Misuse or Overdose (OEI-02-17-00560)*, June 2018.
2. Ensuring Program Integrity in Medicare Fee-for-Service and Effective Administration of Medicare

**Why This Is a Challenge**

In FY 2017, Medicare spent $698.7 billion and provided health coverage to 58.4 million beneficiaries. Medicare spending represents more than 15 percent of all Federal spending. Future spending is expected to increase significantly because of growth in the number of beneficiaries and increases in per capita healthcare costs. The 2018 Annual Report of the Board of Trustees of the Federal Hospital Insurance and Federal Supplemental Medicare Insurance Trust Funds estimates that the Trust Fund for Medicare Part A (Hospital Insurance) will be depleted by 2026. It also projects that spending for Medicare Part B (Medical Insurance) will grow by almost 8.2 percent over the next 5 years, outpacing the U.S. economy, which is projected to grow by 4.7 percent during that time.

The Medicare Program continues to be susceptible to risks associated with volume-driven reimbursement, such as incentives for inappropriate utilization. The Department is working to transform Medicare into a more value-based system with shared accountability for quality, costs, and outcomes. However, given the millions of beneficiaries and hundreds of billions of dollars still associated with traditional Medicare, the Department must continue to ensure the integrity of the existing programs even as it develops new ones (see TMC #4 for more information on ensuring value and integrity in managed care and other innovative payment and service healthcare delivery models).

**Reducing improper payments**

**Key Components of the Challenge**

- Reducing improper payments
- Combating fraud
- Fostering prudent payment policies
- Maximizing the promise of health information technology

**FOCUS ON HOSPICE**

Hospice is an increasingly important benefit for the Medicare population. It can provide great comfort to beneficiaries, their families, and other caregivers at the end of a beneficiary’s life. The number of hospice beneficiaries has grown every year for the past decade. In 2016, Medicare spent about $16.7 billion for hospice care for 1.4 million beneficiaries (compared to $9.2 billion for fewer than 1 million beneficiaries in 2006). With this growth, OIG has identified significant vulnerabilities and has raised concerns about hospice billing, Federal oversight, and quality of care provided to beneficiaries. OIG investigations have also uncovered hospices enrolling beneficiaries without their knowledge or under false pretenses, enrolling beneficiaries who are not terminally ill, billing for services not provided, paying kickbacks, and falsifying documentation.
chiropractic services, care in skilled nursing facilities (SNF), and certain hospital services.

Hospital billing for short inpatient stays also remains a concern. CMS’s enforcement of its 2-midnight policy has been limited. OIG found that hospitals billed for many potentially inappropriate short inpatient stays; for these stays, Medicare paid a total of almost $2.9 billion. OIG also found that hospitals may have financial incentives to use short inpatient stays, and that some hospitals increased their use of these stays, which is inconsistent with the stated goals of the 2-midnight policy.

**Progress in Addressing the Challenge**

HHS and CMS have made several corrective actions for the Medicare FFS program that focus on specific service areas with high error rates, such as home health and inpatient rehabilitation facilities claims. These actions are designed to reduce fraud, waste, and abuse in the Medicare FFS program while ensuring patients receive necessary care.

CMS has put into place new requirements that make identification and recoupment of overpayments easier by using tax identification numbers and provider transaction access numbers in addition to national provider numbers. CMS has also improved identification of overpayments by sharing best practices across Unified Program Integrity Contractors and addressing challenges that hinder their identification of overpayments.

**What Needs To Be Done**

- CMS should take more effective actions to reduce improper payments among provider and supplier types and in geographic locations that present a high risk to the financial integrity of Medicare. This includes focusing on provider types that OIG and CMS have found to have extremely high rates of improper payments, such as chiropractors, home health providers, hospice, SNFs, and high-risk hospital services.
- HHS should continue to address and resolve program integrity weaknesses that OIG has identified. For example, CMS should implement the requirement for home health agencies to obtain surety bonds to ensure that Medicare can recoup at least some of its overpayments and to potentially deter ill-intended providers.
- CMS needs to strengthen oversight for hospice general inpatient billing and SNF billing.

**Combating fraud**

**Key Components of the Challenge**

Stopping fraud in Medicare is vital to safeguarding healthcare resources and protecting beneficiaries. OIG has identified common fraud schemes, such as billing for unnecessary services or services not provided; billing for more expensive services than needed or provided; paying kickbacks to recruiters, providers, and patients; and medical identity theft. Program areas susceptible to widespread fraud include home health, hospice services, DME, ambulance transportation, and clinical laboratory testing. Fraud schemes can become “viral”—spreading and replicating through communities—and can also evolve quickly. This creates challenges for CMS and law enforcement to detect and quickly respond to emerging schemes.

Since June 30, 2011, the Fraud Prevention System (FPS) has continuously run predictive algorithms and other sophisticated analytics nationwide against Medicare FFS claims prior to payment to identify, prevent, and stop fraudulent claims. When performing work to certify the actual and projected savings
and the return on investment related to HHS’s use of FPS, OIG found that HHS might not have the capability to trace the savings from administrative actions back to the originating FPS model or formula. CMS could not track those savings because, according to CMS, that capability was not built into FPS. In addition, CMS did not make use of all pertinent performance results because it did not ensure that contractors’ adjusted savings reported to CMS reflected the amounts certified by OIG, and CMS did not evaluate FPS model performance on the basis of the amounts expected to be prevented or recovered.

CMS needs accurate information to avoid doing business with—and exposing beneficiaries to—untrustworthy actors or ineligible providers. However, fraudulent providers sometimes provide false or incomplete information on ownership and business associations or misrepresent themselves to appear legitimate. Untrustworthy actors may also try to circumvent program safeguards in other ways. For example, an OIG review found that some patient lists supplied by home health agencies were missing Medicare beneficiaries, which excluded them from surveyor inspections. This illustrates a vulnerability that home health agencies could exploit to conceal fraudulent activity or health and safety violations.

**Progress in Addressing the Challenge**

In February 2016, CMS issued a technical direction letter (TDL) to the Zone Program Integrity Contractors (ZPICs or contractors) clarifying how to determine which administrative actions were attributable to the FPS. Additionally, in August 2018, CMS began providing the contractors with an annual report listing administrative actions and associated savings that CMS deemed FPS attributable and those CMS deemed not FPS attributable. This allowed CMS to go one step further and ensure that contractors’ adjusted savings reflected the amounts certified by OIG.

In March 2017, CMS launched an updated FPS version ("FPS 2.0") that modernizes system and user interfaces, improves model development time and performance measurement, and aggressively expands CMS’s program integrity capabilities. During FY 2016, the FPS models generated 688 leads that were included in the ZPICs’ workload, resulting in 476 new investigations and augmented information for 212 existing investigations. CMS has also implemented a system to attribute savings from administrative actions back to specific models. CMS is also revising the FPS savings methodology.

HHS partners with OIG and the U.S. Department of Justice (DOJ) on Health Care Strike Force teams and other healthcare fraud enforcement activities through the Health Care Fraud and Abuse Control (HCFAC) program. Over its 22-year history, the HCFAC program has recovered billions of dollars and has further protected Federal healthcare programs by convicting criminals and excluding providers from participation in Medicare and other Federal healthcare programs.

Most recently, HHS, along with State and Federal law enforcement partners, participated in an unprecedented nationwide healthcare fraud takedown aimed at combating healthcare fraud and the opioid epidemic (see TMC #1 for more information on the opioid epidemic). More than 600 defendants in 58 Federal districts were charged for their alleged participation in schemes involving approximately $2 billion in losses to vital healthcare programs, including Medicare.

CMS partners with OIG and DOJ in many ways to fight fraud. For example, Medicare and Medicaid policy experts, OIG and DOJ law enforcement officials, clinicians, and CMS fraud investigators coordinate before, during, and after the development of fraud leads to expedite referrals and investigation of providers suspected of endangering beneficiaries and/or defrauding Medicare. OIG, CMS, and DOJ also
coordinate with private sector health insurers through the Healthcare Fraud Prevention Partnership and the National Healthcare Anti-Fraud Association.

**What Needs To Be Done**

- CMS should fully employ available program integrity tools to prevent payment to fraudulent providers. For example, CMS must continue improving its oversight and the performance of contractors implementing Medicare provider enrollment safeguards.
- CMS should make better use of the performance results within its FPS to refine and enhance its predictive analytic models.

**Fostering prudent payment policies**

**Key Components of the Challenge**

Medicare should act as a prudent payer on behalf of taxpayers and beneficiaries by instituting economical payment policies. However, in certain contexts, Medicare payment policies, which are generally set by statute, result in Medicare and beneficiaries paying more for care provided in certain settings than for the same care provided in other settings. For example, Medicare could potentially save $4.1 billion over a 6-year period if swing-bed services at critical access hospitals were paid for at the same rates as at SNFs.

Medicare also pays hospitals different amounts for the same care depending on whether the hospital admits beneficiaries as inpatients or treats them as outpatients. Medicare and beneficiaries’ coverage for SNF services and coinsurance costs following discharge also vary depending on their status as hospital inpatients or outpatients, even if they receive the same care during their stay.

Some payment policies create financial incentives that may actually drive up Medicare costs without improving care for beneficiaries. For example, OIG found that Medicare payments to SNFs for therapy greatly exceeded SNFs’ costs for that therapy, creating incentives to bill for unnecessary therapy (see TMCs #4 and #11 for more information on challenges of anticipating and addressing financial incentives in additional areas, including value-based payments and drug pricing and access).

**Progress in Addressing the Challenge**

HHS has been instituting changes to promote more prudent payment policies in some healthcare settings. For example, recent statutory changes require Medicare to stop paying certain new hospital-owned, off-campus, “provider-based” departments that charge higher hospital rates than freestanding facilities that perform the same services for less. CMS projects that this will have saved Medicare approximately $50 million in 2017. CMS finalized the Patient Driven Payment Model, a new payment system for SNFs to be implemented in FY 2020, which bases Medicare payment on beneficiaries’ conditions and care needed rather than on volume of services provided.

**What Needs To Be Done**

- CMS can take actions within existing authorities to mitigate financial risks and quality-of-care risks under the current systems. For example, CMS should reform the payment policy for hospices to align payments to costs and address the financial incentives for hospices to target beneficiaries likely to have long stays.
CMS should evaluate the extent to which Medicare payment rates for therapy should be reduced, as well as adjust Medicare payments to SNFs to eliminate any increases in payments for therapy that are unrelated to changes in beneficiary characteristics. CMS should also use data analytics to target oversight to SNFs that may be inappropriately billing for therapy.

CMS can test and rigorously evaluate the effectiveness and efficiency of new payment and delivery models.

Maximizing the promise of health information technology

Key Components of the Challenge
Leveraging the benefits of Health Information Technology (Health IT) to ensure the appropriate flow of complete, accurate, timely, and secure information and to improve patient care is critical to promoting a value-driven healthcare system. HHS faces challenges in achieving a connected healthcare system in which data, including healthcare data and human services data about social determinants of health, flow freely, as appropriate. Challenges for HHS include ensuring that Health IT companies and providers do not inappropriately block the flow of information, preventing inappropriate payments to participants who do not meet program requirements, ensuring that electronic health records (EHR) are not used as tools for fraud, encouraging adoption and use of Health IT by those not eligible for existing incentive programs, ensuring that patient safety benefits are realized, and encouraging high-value uses of exchanged data. To avoid potential gaps in policy and oversight that could undermine the promise of Health IT, HHS must ensure coordination among internal agencies and other Federal partners that have overlapping responsibility for various aspects of Health IT (see TMC #10 for more information on the intersection of HHS’s data privacy and security).

Progress in Addressing the Challenge
HHS continues to develop programs and policies that foster the development, adoption, and effective use of Health IT to support the appropriate flow of complete, accurate, timely, and secure information within Medicare. As of July 2018, more than 642,500 eligible professionals and hospitals—including critical access hospitals—were actively registered in the EHR incentive programs. CMS and the Office of the National Coordinator for Health IT (ONC) have also undertaken efforts to educate providers about EHR fraud vulnerabilities, including conducting sessions with stakeholders on EHR coding and billing.

HHS also finalized a rule to implement the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) provisions that replaced the Medicare EHR Incentive Program for eligible professionals with a performance category within Merit Based Incentive Payments System (MIPS). Additionally, HHS is in the process of implementing various provisions of the Cures Act that will facilitate the appropriate flow of complete, accurate, timely, and secure data. OIG will play a role moving forward by using its new civil monetary penalty (CMP) authority to enforce information-blocking violations.

What Needs To Be Done

- CMS must ensure that data collected and relied upon for Medicare program purposes are complete, accurate, timely, and secure, and that evolving technologies, such as telemedicine, achieve their intended results.
- HHS must address barriers to the appropriate flow of complete, accurate, timely, and secure data among providers, beneficiaries, and other stakeholders.
- ONC and CMS should strengthen their collaborative efforts to develop a comprehensive plan to address fraud vulnerabilities in EHRs.
- To the extent that resources, cost, and quality performance are measured on the basis of Medicare Parts A and B claims data, CMS must ensure the soundness and reliability of such data.
- CMS should adopt sound record-retention and documentation practices for all of Medicare FFS while being mindful of minimizing the burdens placed on those implementing the practices.

**Key OIG resources**

- Not All Recommended Safeguards Have Been Implemented in Hospital EHR Technology (**OEI-01-11-00570**), December 2013.
3. Ensuring Program Integrity and Effective Administration of Medicaid

**Why This Is a Challenge**
Medicaid is the largest Federal healthcare program, with 67 million individuals enrolled, and represents one-sixth of the national health economy. Medicaid is administered by States, according to Federal requirements. The program is funded jointly by the Federal Government and States. For FY 2017, CMS estimated Federal and State Medicaid expenditures of $592 billion. Expenditures are projected to increase at an average annual rate of 5.7 percent and reach over $1 trillion by 2026. Effectively administering the Medicaid program takes on heightened urgency as it continues to grow in spending and the number of beneficiaries served. The Department provides States with flexibility to administer their Medicaid programs, so they can design innovative waivers based on the unique needs of their Medicaid enrollees (see TMC #4 for more information on challenges specific to managed care).

**Key Components of the Challenge**
- Improving the reliability of national Medicaid data
- Reducing improper payments
- Combating fraud
- Ensuring appropriate Medicaid eligibility determinations

**Improving the reliability of national Medicaid data**

**Key Components of the Challenge**
Data is an essential tool for detecting fraud, waste, and abuse and administering the program effectively and efficiently. However, OIG’s work has identified numerous issues with the completeness and reliability of Medicaid data. The lack of reliable national Medicaid data hampers States’, CMS’s, and other stakeholders’ ability to quickly detect potential fraud, waste, or quality concerns at the State, multi-State, and national levels. While all 50 States, the District of Columbia, and Puerto Rico are now reporting Transformed Medicaid Statistical Information System (T-MSIS) data, data must be reliable, timely, and accurate to be of use to States, CMS, and other stakeholders in making comparisons across all States and identifying national trends and vulnerabilities.

**Progress in Addressing the Challenge**
CMS’s efforts to work with States to report T-MSIS data has led to all 50 States, the District of Columbia, and Puerto Rico now reporting T-MSIS data. CMS also reported efforts underway to improve T-MSIS data through various data quality methods. On August 10, 2018, CMS issued a State Health Official letter that provided additional guidance to States on T-MSIS implementation. The letter stated that CMS expects States to resolve data quality for 12 top-priority items no later than 6 months after the date of the letter; for any State that cannot meet that timeframe, CMS would request a corrective action plan. CMS also anticipates making T-MSIS research-ready files available in 2019.

**What Needs To Be Done**
- CMS and States need to make complete, reliable, accurate, and timely T-MSIS data a management priority. In doing so, CMS should establish and adhere to a deadline for when national T-MSIS data will be available for program oversight and management.
- CMS must ensure that the same data elements are consistently reported and uniformly interpreted across States and use its enforcement authorities when States are not submitting timely and complete data.
Reducing improper payments

Key Components of the Challenge
Reducing improper payments to providers is a critical element in protecting the financial integrity of the Medicaid program. In FY 2017, HHS reported that it did meet the FY 2016 reduction target of 9.57 percent and reported an actual 10.10 percent improper payment rate in the Medicaid program. CMS must do more to ensure that Medicaid payments are made to the right providers, for the right amounts, for the right services, on behalf of the right beneficiaries. OIG audits have identified substantial improper payments to providers across a variety of Medicaid services, including school-based services, nonemergency medical transportation, targeted case management services, and personal care services.

Progress in Addressing the Challenge
CMS has engaged with State Medicaid agencies to develop corrective action plans that address State-specific reasons for improper payments as a part of CMS’s Payment Error Rate Measurement (PERM) program, which measures Medicaid improper payments. In 2018, CMS also resumed the Medicaid Eligibility Quality Control program requiring States to engage in pilots studying certain eligibility determinations for accuracy, a program meant to complement State PERM reviews. CMS also engaged a contractor to design an Express Lane Eligibility error rate measurement methodology for States. CMS also has facilitated national best practices calls to share ideas across States, provided State education through the Medicaid Integrity Institute, offered ongoing technical assistance, and provided additional guidance as needed to address the root causes of improper payments. Time will tell whether CMS’s efforts to measure and provide guidance yield reductions in improper payments.

What Needs To Be Done
- CMS should continue to engage with State Medicaid agencies to develop corrective action plans and provide specific guidance to States regarding services and benefits most vulnerable to improper payments.

Combating fraud

Key Components of the Challenge
A useful strategy to prevent Medicaid provider fraud is to keep bad actors intent on committing fraud from enrolling in the program. However, States are not screening high-risk providers with all the tools at their disposal, including site visits and required fingerprint-based criminal background checks during enrollment. In addition, sharing enrollment data across States and with Medicare enrollment data systems would streamline the Medicaid enrollment process and reduce the chance for error within any one database. Also, national Medicaid data can be used to identify fraud schemes and other vulnerabilities that cross State lines. Identifying such schemes in one State can alert other States to patterns of fraudulent or abusive practices that may be occurring in their jurisdiction. However, the lack of reliable national Medicaid data hampers enforcement efforts. For example, OIG published a data brief identifying concerns about extreme use and questionable prescribing of opioids in Medicare Part D. Unfortunately, OIG currently cannot replicate this type of analysis at a national level in Medicaid without national data such as what has been promised through T-MSIS.
Progress in Addressing the Challenge
CMS actively works with States on site visits and fingerprint-based criminal background checks to identify barriers related to State implementation and compliance with Federal requirements. This work includes issuing guidance, known as the Medicaid Provider Enrollment Compendium, to assist States in strengthening their provider screening and enrollment processes. To further streamline Medicaid provider enrollment, CMS has employed the use of a data compare tool, which allows States to compare their provider population against the data on those providers already screened and enrolled in Medicare. CMS also engages with States at least monthly via technical assistance calls when concerns, questions, and best practices are addressed and shared.

What Needs To Be Done
- CMS should continue to work directly with States to implement tools like site visits or fingerprint-based criminal background checks for high-risk providers.
- CMS should develop a central repository or “one-stop shop” with provider information that all States and Medicare can use. This could reduce data-collection duplication and burdens on States and providers and improve the completeness and accuracy of the data available to these programs.
- CMS should establish a deadline for when national T-MSIS data will be available for multistate program integrity efforts.

Ensuring appropriate Medicaid eligibility determinations

Key Components of the Challenge
CMS faces challenges in ensuring that States appropriately apply criteria for Medicaid eligibility. The Affordable Care Act allowed States to expand Medicaid eligibility for certain low-income adults and claim a higher Federal Medical Assistance Percentage for those who are newly eligible under the expansion. OIG reviews in three States estimated that more than $1.2 billion in Federal Medicaid payments has been made on behalf of potentially ineligible and ineligible beneficiaries. Lack of beneficiary eligibility systems functionality was a key contributor to these payments.

Progress in Addressing the Challenge
CMS indicated that it will initiate audits of State beneficiary eligibility determinations in States previously reviewed by OIG and will resume measuring eligibility under the PERM program in FY 2019. These audits will include an assessment of the impact of changes to State eligibility policies because of Medicaid expansion; for example, CMS will review whether beneficiaries were found eligible for the correct Medicaid eligibility category.

What Needs To Be Done
- CMS should closely monitor States to ensure they are correctly determining Medicaid eligibility for beneficiaries.
- CMS should continue to work with States to ensure that eligibility systems are able to verify eligibility, develop and implement written policies and procedures to address vulnerabilities, and undertake redeterminations as appropriate.
Key OIG resources

- **Medicaid Fraud and Overpayments: Problems and Solutions (OIG Testimony)**, June 2018.
- **Improper Payments in State-Administered Programs: Medicaid (OIG Testimony)**, April 2018.
- **Medicaid Enhanced Provider Enrollment Screenings Have Not Been Fully Implemented (OEI-05-13-00520)**, May 2016.
- **California Made Medicaid Payments on Behalf of Newly Eligible Beneficiaries Who Did Not Meet Federal and State Requirements (A-09-16-02023)**, February 2018.
4. Ensuring Value and Integrity in Managed Care and Other Innovative Healthcare Payment and Service Delivery Models

**Why This Is a Challenge**
The HHS Secretary has made the transition to value-based care a top priority for the Department. HHS continues to enact reforms in Medicare and Medicaid that are designed to promote quality and value of care. Understanding what constitutes value and whether it is delivered is a challenge in complex healthcare programs and services. As managed care continues to play an increasingly important role in the Medicare and Medicaid programs, ensuring that beneficiaries get the services they need is essential. Finally, developing and implementing managed care and other innovative models in ways that promote innovation and effectiveness, while also protecting against fraud, waste, and abuse, is a significant challenge.

**Key Components of the Challenge**
- Ensuring effectiveness and integrity in new models
- Combatting provider fraud and abuse
- Fostering compliance by managed care organizations

**Ensuring effectiveness and integrity in new models**

**Key Components of the Challenge**
HHS continues to seek innovative ways to move Medicare and Medicaid from volume-based payment to value-based payment. This shift involves the design of new systems, including through experimentation and development of new payment and coordinated care approaches. Developing effective incentives and policies can be difficult given complexities of the programs, the populations they serve, and the national healthcare system. HHS faces obstacles in correctly measuring the value of care. It can be a challenge to design measures that effectively incentivize high-quality care without being overly prescriptive or burdensome to providers. The Department is exploring—via a Deputy Secretary led Regulatory Sprint to Coordinated Care—whether better care coordination can be fostered through changes to existing laws that some view as barriers to coordination, including certain fraud and abuse laws administered by CMS and OIG, as well as certain SAMHSA and Office for Civil Rights (OCR) regulations.

CMS continues to manage a range of programs and test models through the Center for Medicare and Medicaid Innovation that address value-driven system reforms to improve quality of care in Medicare and Medicaid and reduce expenditures. New payment structures, business arrangements among providers, and incentives all give rise to risk-management challenges. In pursuing innovative models to improve the healthcare system, CMS must take steps to prevent programs and policies from having unintended consequences, such as misaligned incentives or abusive practices.

**Progress in Addressing the Challenge**
CMS continues to develop and administer new models and existing models and value-based programs, such as the Quality Payment Program and the Medicare Shared Savings Program. CMS has proposed changes to the Medicare Shared Savings Program to increase savings for the Trust Funds and mitigate losses, reduce gaming opportunity, and increase program integrity. CMS continues to coordinate with OIG on tailored waivers of fraud and abuse laws, where needed and authorized, to test and carry out
value-based models. HHS has published Requests for Information to seek stakeholder input on ways to revise certain fraud and abuse laws to promote care coordination without undermining their original fraud prevention purposes.

In 2017, CMS launched the Meaningful Measures Initiative. CMS has sought to enhance quality measurement by focusing on high-impact areas for quality improvement, identifying outcome-based measures that are most useful to patients and clinicians, minimizing the level of provider burden, and aligning the measures across programs.

What Needs To Be Done

- In testing value-based care models, CMS must continue to focus on program integrity risks, incorporate safeguards to reduce them, and promptly correct identified issues. This is especially important for models that introduce new payment incentives, which might lead to new fraud schemes, and for models for which waivers of payment, coverage, or fraud and abuse laws may have been issued.
- Where applicable, CMS must clearly define actionable and meaningful quality measures, ensuring their reliability and accuracy. CMS and other agencies currently using quality measurements should further align these efforts to reduce unnecessary provider burden.
- Moving forward, HHS will need to ensure that any metrics are effective, evidence-based measures for quality improvement.

Combating provider fraud and abuse

Key Components of the Challenge
Managed care is the primary delivery system for Medicaid and covers approximately 80 percent of all enrollees. In Medicare, one-third of beneficiaries are enrolled in Medicare Advantage Organizations (MAOs). Fraud, waste, and abuse in Medicaid and Medicare cost taxpayers billions of dollars every year. MAOs and Medicaid Managed Care Organizations (MCOs) are essential to safeguarding the Medicare and Medicaid programs and taxpayer dollars. However, weaknesses exist in their efforts to identify and address fraud and abuse. Limitations in Medicare and Medicaid encounter data also hinder efficient and effective program oversight and program integrity (see TMC #3 for more information on Medicaid data limitations). In addition, CMS does not require MAOs to include the identifiers for ordering and referring providers in their encounter data submissions, which makes it more difficult to detect potential fraud, waste, and abuse through data analytics.

Managed care plans often fail to effectively identify and address fraud and abuse by their providers. CMS requires MAOs and Medicaid MCOs to implement compliance plans that include measures to prevent, detect, and correct instances of fraud, waste, and abuse; however, these vary widely among the plans, as does the detection of suspected fraud. In Medicaid managed care, program integrity responsibilities are even more dispersed, as they are shared among CMS, States, and MCOs. This makes effective oversight by CMS more complex and challenging.

Progress in Addressing the Challenge
CMS is working to validate the completeness and accuracy of MAO and Medicaid MCO encounter data. CMS has increased its efforts to enhance data accuracy and recently released best practice guidance for MAOs to improve encounter data submission. CMS is also working with States to provide technical
assistance and education to identify and share best practices for improving Medicaid MCO identification and referral of cases of suspected fraud or abuse.

CMS conducts State Program Integrity Reviews, which include State oversight of Medicaid MCOs and compliance with applicable Federal regulations. For those States not compliant, CMS has provided technical assistance and requested corrective plans to address any identified concerns.

**What Needs To Be Done**

- CMS should take further actions to ensure the completeness, validity, and timeliness of MAO and Medicaid encounter data. This includes requiring MAOs to report identifiers for ordering and referring providers. Having comprehensive data is crucial to safeguard the programs’ integrity and solvency and to ensure that beneficiaries are receiving quality care.
- CMS should work with its contractors and with States to make improvements in efforts to identify and address fraud and abuse.
- CMS should work to ensure that appropriate information and referrals are sent to law enforcement.

**Fostering compliance by managed care organizations**

**Key Components of the Challenge**

HHS must be vigilant about risks posed to HHS funds and beneficiaries by MAOs and Medicaid MCOs contracted to deliver healthcare services. These entities have incentives to maximize the capitated payments received while minimizing their costs in providing healthcare services. In Medicaid, OIG has found significant vulnerabilities in provider availability, which is a key indicator for access to care. Without adequate access, enrollees cannot receive the preventive care and treatment necessary to achieve positive health outcomes and improved quality of care. In Medicare, OIG found high rates of appealed denials are overturned, and CMS commonly cites MAOs for inappropriate denials in its audits. This raises concerns that some beneficiaries and providers may not be getting services and payments that MAOs are required to authorize under the Medicare program.

**Progress in Addressing the Challenge**

CMS has initiated audits to ensure that Medicaid MCOs are complying with the medical loss ratio standard that they spend at least 85 percent of their capitation rate on medical care and activities that improve beneficiary quality of care. CMS is also working to ensure that beneficiaries have adequate access to providers. For example, CMS requires State Medicaid agencies to develop and implement provisions that ensure beneficiaries have adequate access to Medicaid covered services. Furthermore, CMS published a toolkit and resource guide to assist States with ensuring adequate provider networks. In 2017, CMS issued guidance and best practices regarding increasing the accuracy of provider directories and stated that it plans to perform directory monitoring activities that could result in enforcement actions for MAOs.

**What Needs To Be Done**

- CMS should work with States and MAOs to see that plans’ networks are substantial enough to ensure timely access to care for Medicaid and Medicare managed care beneficiaries.
- CMS should enhance its oversight of MAO contracts including those with extremely high overturn rates and/or low appeal rates and take corrective action as appropriate.
Key OIG resources

- *Followup Review: CMS’s Management of the Quality Payment Program (OEI-12-17-00350)*, December 2017.
- *Weaknesses Exist in Medicaid Managed Care Organizations’ Efforts to Identify and Address Fraud and Abuse (OEI-02-15-00260)*, July 2018.
- *Medicare Advantage Organizations’ Identification of Potential Fraud and Abuse (OEI-03-10-00310)*, February 2012.
- *Medicare Advantage Encounter Data Show Promise for Program Oversight, But Improvements are Needed (OEI-03-15-00060)*, January 2018.
- *The MEDIC Produced Some Positive Results but More Could be Done to Enhance its Effectiveness (OEI-03-17-00310)*, July 2018.
- *Access to Care: Provider Availability in Medicaid Managed Care (OEI-02-13-00670)*, December 2014.
5. **Protecting the Health and Safety of Vulnerable Populations**

**Why This Is a Challenge**

HHS programs provide critical health and human services to many vulnerable populations in many different settings. Therefore, HHS must ensure that the individuals in HHS programs have access to and receive high-quality care and services and are protected from abuse or neglect.

HHS, through the Administration for Children and Families’ (ACF’s) Office of Refugee Resettlement (ORR), is responsible for the ensuring the shelter and care of thousands of unaccompanied alien children (UAC) who enter the U.S. without legal status. ACF also administers the Child Care and Development Fund (CCDF) program and provides funding to State foster care programs. Ensuring that these children have access to safe, high-quality care remains a longstanding challenge for HHS.

Additionally, healthcare providers such as nursing homes, group homes, and hospices have continued to experience issues with ensuring quality of care and safety for vulnerable individuals. HHS has not always acted to correct deficiencies in these facilities.

### Ensuring the safety and security of unaccompanied children in HHS care

**Key Components of the Challenge**

- Ensuring the safety and security of unaccompanied children in HHS care
- Addressing substandard nursing home care
- Reducing problems in hospice care
- Mitigating risks to individuals receiving home- and community-based services
- Ensuring access to safe and appropriate services for children
- Addressing serious mental illness

Most UAC are initially taken into custody by the Department of Homeland Security (DHS) at the U.S. border and transferred into ORR’s custody. ORR provides temporary shelter, care, and other related services to UAC, often in facilities operated by grantees that receive funding from ORR. HHS has encountered challenges caring for UAC in ORR grantee facilities, especially when the UAC program experiences a sudden surge in the number and/or needs of children. In FY 2017 alone, more than 40,000 UAC were referred to ORR custody, a dramatic increase from the 13,625 UAC referred in FY 2012.¹¹ Challenges also exist to ensuring the safety and well-being of UACs after being released to sponsors.

OIG reviews of ORR grantees determined that some grantees may not have complied with certain program requirements, including releasing children to sponsors without conducting all required background checks and documenting that public record checks were conducted on sponsors. As a result, ORR does not have assurance that all grantees properly released children to sponsors.

---

**Progress in Addressing the Challenge**

HHS has increased its efforts to promote the safety and well-being of UAC after their release from HHS care. ORR continues to provide case management services to the most vulnerable children; additionally, ORR now attempts to contact children and sponsors 30 days after release and operates helplines available to all children and sponsors.

HHS has also improved its coordination with DHS related to UAC. In February 2016, HHS and DHS signed a formal agreement to outline each Department’s roles and responsibilities related to UAC. In 2017, OIG also reported that HHS had improved its coordination with DHS and increased its efforts to promote the safety and well-being of UAC after their release from HHS custody.

**What Needs To Be Done**

- ACF should continue to ensure the health and safety of children in ORR care, especially when the program experiences a sudden change in the number and/or needs of children.
- OIG will continue to provide oversight of the UAC program. For instance, OIG is conducting ongoing audits of ORR facilities’ compliance with health and safety requirements as well as internal financial controls. OIG is also conducting a review focusing on the care and well-being of children residing in ORR-funded facilities.
- OIG will continue to examine instances of potential criminal misconduct to determine whether an investigation or referral is needed.

**Addressing substandard nursing home care**

**Key Components of the Challenge**

Many nursing home residents are at risk of abuse and neglect. OIG identified instances of nursing facilities’ failing to identify and report abuse and neglect as required, as well as deficiencies in procedures for enforcing requirements. For example, OIG identified 134 Medicare beneficiaries whose injuries may have been the result of potential abuse or neglect that occurred from January 1, 2015, through December 31, 2016. OIG also identified instances where States fell short in conducting investigations of serious nursing home complaints within required timeframes.

**Progress in Addressing the Challenge**

HHS has taken steps to promote quality and prevent abuse and neglect. This includes making progress in developing the SNF Value-Based Purchasing Program, planned for launch in FY 2019. HHS has improved reporting of accurate nursing home quality information through the Nursing Home Compare Program and Five-Star Quality Rating System. HHS also works closely with law enforcement partners at DOJ and the Elder Justice Interagency Working Group to promote better care for older adults and to prosecute providers that subject them to abuse or neglect.

CMS has revised its requirements and guidelines for nursing home surveyors to focus on assessing adverse event identification and reductions. To help raise awareness of adverse events in post-acute care, CMS collaborated with the Agency for Healthcare Research and Quality to promote and create a final list of potential nursing home events. Additionally, OIG has entered quality-of-care corporate integrity agreements with more than 40 nursing home companies covering more than 1,000 facilities. These agreements require providers to retain an independent monitor to perform clinical and quality reviews and assessments of the delivery of quality healthcare.
What Needs To Be Done

- HHS should implement strategies to strengthen oversight of nursing homes and improve nursing care. For example, HHS should monitor how often nursing home residents are hospitalized and develop additional resources to help providers avoid adverse events.
- HHS must improve internal controls, as well as surveyor guidance and training, to ensure that nursing homes correct deficiencies and prevent recurrence of safety and quality issues.
- CMS should improve identification and reporting of nursing home resident abuse and neglect. For instance, CMS should take immediate action to ensure that incidents of potential abuse or neglect of Medicare beneficiaries residing in SNFs are identified and reported.
- To reduce incidence of adverse events, CMS should instruct nursing home surveyors to review facility practices for identifying and reducing adverse events, as well as assist States that are failing to meet timeframes for investigating nursing home complaints.

Reducing problems in hospice care

Key Components of the Challenge
OIG’s body of work on the Medicare hospice benefit has identified numerous quality of care problems for Medicare beneficiaries in the hospice general inpatient care setting. For example, OIG found that most beneficiaries, including beneficiaries with complex needs, do not see a hospice physician, and key services to control pain and manage symptoms are sometimes lacking. OIG also raised concerns about hospice beneficiaries and their caregivers not receiving the information they need to make informed decisions.

Additionally, investigations have uncovered hospices enrolling patients without the beneficiary’s knowledge or under false pretenses, enrolling beneficiaries who are not terminally ill, billing for services not provided, paying kickbacks, and falsifying documentation.

Progress in Addressing the Challenge
HHS launched the Hospice Compare web site to facilitate public access to hospice quality data. Medicare Administrative Contractors have targeted their monitoring toward hospices that rely heavily on nursing facility residents. By seeking out these residents, hospices may be looking to increase their profits by only serving beneficiaries associated with longer but less complex care. Additionally, HHS is also taking enforcement actions against hospices fraudulently enrolling beneficiaries.

What Needs To Be Done

- CMS should improve quality of care and consumer protections by strengthening the survey process. This will better ensure that hospices provide beneficiaries with needed services and quality care.
- CMS should promote physician involvement and accountability to guarantee that beneficiaries receive appropriate care, as well as take steps to tie payments to beneficiary care needs and quality of care to confirm that services rendered adequately serve beneficiaries’ needs.
- CMS can take steps to make available consumer-friendly information that explains the hospice benefit to families and caregivers.
Mitigating risks to individuals receiving home- and community-based services

**Key Components of the Challenge**

In recent decades, healthcare has shifted from institutional care settings to more community-based services and support, such as group homes. These settings provide beneficiaries greater independence, increased flexibility for providers, and access to more opportunities than in an institutional setting. However, OIG has found that group home health and safety policies and procedures are not always followed, leaving beneficiaries at risk of serious harm. This is a systemic problem; in recent years, 49 States had media reports of health and safety problems in group homes.  

Payment and quality vulnerabilities also exist in home settings. Reported fraud and abuse incidents in personal care services (PCS) are a substantial and growing percentage of MFCU cases and outcomes. OIG work has demonstrated that existing program safeguards intended to ensure medical necessity, patient safety, and quality and prevent improper payments were often ineffective. In addition, OIG interviews with Medicaid beneficiaries revealed quality-of-care concerns including serious allegations including physical abuse or threats of abuse, property theft, and patient abandonment. Without proper control and oversight mechanisms, unscrupulous attendants could expose beneficiaries to substandard quality of care and injury.

**Progress in Addressing the Challenge**

In an HHS joint report, the Administration for Community Living (ACL), the HHS OCR, and OIG developed Model Practices that provide States with a roadmap for how to implement better health and safety practices. The report provides States with models for incident management and investigation, incident management audits, mortality reviews, and quality assurance. In response to the Joint Report’s suggestions, CMS issued an Informational Bulletin in June 2018 to encourage States to implement compliance oversight programs for group homes, such as the Model Practices.

HHS is working with MFCUs to prevent, detect, and take enforcement action against PCS providers suspected of fraud or abuse. The Cures Act mandated that CMS implement the electronic visit verification (EVV) system for all Medicaid PCS and home health services that require an in-home visit by a provider. CMS reported that it currently has reviewed 30 advance planning documents (APDs) from 31 States (including the Arizona and Hawaii joint APD), and 11 States have implemented EVV.

**What Needs To Be Done**

- CMS should continue to implement the Model Practices outlined in the HHS joint report. CMS needs to take immediate action in response to serious health and safety findings in home- and community-based services providers.
- CMS must also help ensure successful State implementation of EVV for all Medicaid PCS by January 1, 2020, and for home health services by January 1, 2023.
- CMS should issue policies and procedures to ensure effective reporting of critical incidents.

---


Ensuring access to safe and appropriate services for children

Key Components of the Challenge
OIG has identified vulnerabilities related to CCDF childcare providers who received neither a verified background check nor the necessary training, based on State requirements in place prior to changes in Federal requirements. In addition, OIG audits conducted in 10 States found that 96 percent of CCDF childcare providers visited had at least one health and safety violation. OIG also found that more ACF oversight of States’ CCDF programs is needed. For instance, some States’ monitoring requirements for CCDF childcare providers did not always meet recommendations issued by ACF prior to changes in Federal requirements. States also reported limitations in technology, resources, and coordination as challenges to program integrity. Taken together, these findings highlight the need for stronger ACF and State oversight to ensure that safe, high-quality care is provided to children.

In State foster care programs, OIG found that nearly one-third of children in foster care enrolled in Medicaid did not receive required health screenings. Additionally, some States’ protocols for the use and monitoring of psychotropic medications for children in foster care were lacking treatment planning and medication monitoring. OIG has also identified instances in which States did not always ensure that documentation existed that Title IV-E eligible children received required healthcare and case management services.

Progress in Addressing the Challenge
HHS is working with States to implement expanded background checks for childcare providers mandated by the reauthorization of the Child Care and Development Block Grant Act of 2014. States are in the process of designing and implementing health and safety training for all providers before care begins and ongoing as professional development. HHS is also implementing a new on-site monitoring process to ensure that States are meeting Federal childcare requirements.

ACF continues to provide oversight of State compliance with Federal healthcare oversight requirements for children in foster care through ongoing program administration, and on-site monitoring through Child and Family Services Reviews, and technical assistance to State child welfare agencies to promote best practices. Additionally, ACF plans to engage State foster care managers to discuss how to improve oversight of psychotropic medications for children in foster care. CMS is also working with States to reduce inappropriate prescribing of antipsychotic drugs for children in foster care and to improve access to dental care for children in Medicaid.

What Needs To Be Done
- ACF needs to ensure that States are complying with required health and safety standards for childcare providers and examine the effectiveness of program integrity and fraud-fighting activities.
- ACF needs to improve its oversight of State foster care programs to ensure that children are receiving required health screenings in a timely manner, as well as treatment planning and medication monitoring. Specifically, ACF should improve compliance and strengthen State requirements to protect children at risk for inappropriate psychotropic medication treatment and prescribing.
Addressing serious mental illness

**Key Components of the Challenge**

In 2016, nearly one in five adults aged 18 or older in the U.S. (about 44.7 million) lived with a mental illness, and only 43 percent (about 19.2 million) of these adults received mental health treatment in the prior year. Additionally, in 2016, roughly 1 in 25 adults (about 9.8 million) in the U.S., age 18 and older, battled a serious mental illness, such as a psychotic or major depressive disorder.

Medicare and Medicaid both serve significant patient populations in need of mental health services. However, beneficiaries may experience barriers to accessing care, including being limited both geographically and by type of service. The Interdepartmental Serious Mental Illness Coordinating Committee has found that relatively few adults with serious mental illness receive effective treatments, effective treatment models that exist are not widely available, most counties in the U.S. face shortages of mental health professionals, and most States report insufficient psychiatric crisis response capacity as well as insufficient numbers of psychiatric hospital beds. OIG has ongoing work examining reported access issues in certain State Medicaid managed care programs.

**Progress in Addressing the Challenge**

As required under the Cures Act, HHS released the Action Plan for Enhanced Enforcement of Mental Health and Substance Use Disorder Coverage in April 2018, which focuses on improvement of Federal and State coordination related to the enforcement of certain mental health and substance use disorder parity provisions. The Cures Act also authorized a new Assertive Community Treatment grant program for individuals with a serious mental illness, which helps communities improve behavioral health outcomes by reducing hospitalization rates of patients with serious mental illness.

In addition, mental healthcare has been included in Essential Health Benefits since January 1, 2014. The Mental Health Parity and Addiction Equity Act (P.L. 110-343) requires Medicaid and CHIP programs to comply with mental health and substance use disorder parity requirements. On March 29, 2016, CMS published a final rule applying these requirements to certain Medicaid plans and all CHIP programs, resulting in the expansion of parity protections to about 23 million more individuals. In 2016, HHS participated in the White House Mental Health and Substance Abuse Disorder Parity Task Force, which issued recommendations to Federal agencies on supporting consumers, improving parity implementation, and enhancing parity compliance and enforcement. In response to the Parity Task Force’s findings, HHS created a Mental Health and Substance Abuse Disorder Parity website, which provides parity-specific resources to consumers and providers, as well as updates on new ways Federal agencies enforce and clarify parity regulations.

---


HHS is increasing grant funding to develop strategies to expand access to mental health services and for mental health awareness training. New methods, including telemedicine, are also increasingly used to provide increased mental health access, particularly in rural areas. The Bipartisan Budget Act of 2018 expanded telehealth services for Medicare Advantage plans and Accountable Care Organizations.

**What Needs To Be Done**

- While HHS agencies have taken steps to increase mental health parity and funding for mental health services, they can take additional steps to increase the access and quality of mental health services, particularly for serious mental illness.
- CMS should improve efforts to ensure beneficiaries have appropriate access to mental health services and to reduce barriers to care.
- HHS can take steps to implement the Mental Health and Substance Abuse Disorder Parity Task Force’s recommendations.

**Key OIG resources**

- HHS’s Office of Refugee Resettlement Improved Coordination and Outreach to Promote the Safety and Well-Being of Unaccompanied Alien Children (OEI-09-16-00260), July 2017.
- Early Alert: CMS Has Inadequate Procedures to Ensure That Incidents of Potential Abuse or Neglect at Skilled Nursing Facilities Are Identified and Reported in Accordance With Applicable Requirements (A-01-17-00504), August 2017.
- Vulnerabilities in the Medicare Hospice Program Affect Quality Care and Program integrity: An OIG Portfolio (OEI-02-16-00570), July 2018.
- Some WA State Group-Care Facilities for Children in Foster Care Did Not Always Comply with State Health and Safety Requirements (A-09-16-01006), March 2018.
- Series of OIG reports on childcare providers’ compliance with State health and safety requirements (http://oig.hhs.gov/oas/child-care/).
- Child Care and Development Fund: Monitoring of Licensed Child Care Providers (OEI-07-10-00230), November 2013.
- More Effort Is Needed to Protect the Integrity of Child Care and Development Fund (OEI-03-16-00150), July 2016.
- Treatment Planning and Medication Monitoring Were Lacking for Children in Foster Care Receiving Psychotropic Medication (OEI-07-15-00380), September 2018.
- Ohio Did Not Always Comply with Requirements Related to the Case Management of Children in Foster Care (A-05-16-00022), May 2018.
- Oklahoma Did Not Always Comply with Requirements for Providing Health Care Services to Children in Foster Care (A-06-16-07006), February 2018.
6. Improving Financial and Administrative Management and Reducing Improper Payments

**Why This Is a Challenge**
HHS is the largest civilian agency in the Federal Government. In FY 2017, HHS reported total budgetary resources of approximately $1.1 trillion. Responsible stewardship of HHS programs is vital, and operating a financial management and administrative infrastructure that employs appropriate safeguards to minimize risk and provide oversight for the protection of resources remains a challenge for HHS. Due to their size, HHS programs account for some of the largest estimated improper payment amounts. HHS must also ensure the completeness, accuracy, and timeliness of any financial and program information provided to other entities, both internal and external to the Federal Government.

**Key Components of the Challenge**
- Addressing weaknesses in financial management systems
- Addressing Medicare trust fund issues/social insurance
- Reducing improper payments
- Improving contract management
- Implementing the DATA Act

**Addressing weaknesses in financial management systems**

**Key Components of the Challenge**
OIG continues to report a material weakness in HHS’s financial management systems related to inadequate internal controls over segregation of duties, configuration management for approved changes to HHS financial systems, and access to HHS financial systems. OIG continues to report that HHS does not substantially comply with requirements for financial system management because of these issues. Under the *Federal Financial Management Improvement Act of 1996*, Federal agencies must establish and maintain financial management systems and OIGs must report on compliance by their respective agency. These systems help agencies ensure operational effectiveness and efficiency, financial reporting reliability, and compliance with applicable laws and regulations.

**Progress in Addressing the Challenge**
HHS has continued to take corrective actions to resolve the IT-related deficiencies reported in the Agency Financial Report (AFR). In FY 2017, the Information Technology Material Weakness Working Group continued its HHS-wide focus on corrective actions. As a result, many prior-year control deficiencies related to user access, configuration management, and segregation of duties have improved. OIG noted investments and other actions that led to the remediation of these findings and which should improve internal controls over key financial management systems.

**What Needs To Be Done**
- HHS still needs to take additional actions to address and resolve the material weakness in its financial management systems.
- HHS should continue to work to control user access.
- HHS should ensure proper approval of system changes and maintain appropriate documentation that supports the approval of these changes.
- HHS should ensure appropriate segregation of duties so that no one employee can both enter and approve information entered into HHS financial management systems.
Addressing Medicare trust fund issues/social insurance

Key Components of the Challenge
The Statement of Social Insurance (SOSI) presents the actuarial present value of (1) contributions and tax income (excluding interest income); (2) scheduled expenditures; and (3) the difference between the two for all current and future participants (open group) of the Medicare program for the projection period, which covers 75 years. The Statement of Changes in Social Insurance Amounts (SCSIA) reconciles the beginning and ending open group measures and presents the components of the changes for 2 years. These statements cover the Medicare FFS, Medicare Advantage, and Medicare Prescription Drug Benefit programs, and the amounts they disclose are based on current law. According to the 2018 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds, the Trustees assume that the various cost-reduction measures included in the Affordable Care Act will occur as current law requires. The Trustees stated that to achieve this outcome, healthcare providers would have to realize productivity adjustments at a faster rate than experienced historically. The Trustees also stated that should healthcare providers be unable to transition to more efficient models of care delivery and achieve productivity increases commensurate with economy-wide productivity and if the provider reimbursement rates paid by commercial insurers continue to be based on the same negotiated process in use, the availability and quality of healthcare received by Medicare beneficiaries under current law would fall short when compared to private health insurance. The Trustees also stated in the 2018 report that the Federal Hospital Insurance Trust Fund now is expected to be depleted by 2026 and that spending for Federal Supplementary Medical Insurance is expected to exceed inflation in the next 5 years.

The Medicare Board of Trustees included in the Annual Trustees Report an alternative scenario to illustrate, where possible, the potential understatement of Medicare costs and projection results. Since 2010, OIG has noted the inherent difficulties in projecting growth in healthcare costs over time and issued a disclaimer of opinion on the SOSI and SCSIA based on these uncertainties.

Progress in Addressing the Challenge
In FY 2017, HHS continued to present an illustrative alternative scenario to the current legal projections for Medicare to show the potential magnitude on Medicare outlays if certain components of current law are not sustainable. According to the CMS Chief Actuary, the techniques and methodology used to evaluate the financial status of the Federal Hospital Insurance Trust Fund and the Federal Supplementary Medical Insurance Trust Fund are based on sound principles of actuarial practice. With certain caveats, the principal assumptions used and the resulting actuarial estimates are individually, and in the aggregate, reasonable for evaluating the financial status of the trust funds. The Federal Accounting Standards Advisory Board (FASAB) does not have any active or planned projects that would revise existing guidance related to SOSI. OIG continues to expect to issue a disclaimer of opinion on the SOSI and SCSIA until the variances between income and expenditures between current law and the illustrative alternative scenario become much less significant.

What Needs To Be Done

- HHS should continue to work with the CMS Chief Actuary to analyze the Patient Protection and Affordable Care Act and its impact on providers’ ability to sustain the productivity adjustments. The ability to sustain these productivity adjustments would greatly narrow the large variance between current law and the illustrative scenario.
➢ HHS should continue to support actions needed to ensure the long-term viability of the Federal Hospital Insurance Trust Fund.
➢ HHS should continue to work with FASAB to revise the accounting standards for SOSI and SCSIA.

Reducing improper payments

Key Components of the Challenge
Reducing improper payments is a critical element in protecting the financial integrity of HHS programs. Although not all improper payments constitute fraud, all improper payments pose a risk to the financial security of Federal programs. Pursuant to the Improper Payments Information Act of 2002 (IPIA), as amended, Federal agencies are required to provide uniform, annual estimates on improper payments and their efforts to reduce them for high risk programs. In the FY 2017 AFR, HHS reported improper payments of more than $90 billion for seven of the eight programs designated high risk and susceptible to improper payments. In the audit report of the HHS’s FY 2017 AFR, published in May 2018, OIG found that while HHS met many requirements, HHS did not meet all IPIA requirements. Specifically, HHS did not report an improper payment estimate for the Temporary Assistance for Needy Families (TANF) program, as HHS does not believe it has the statutory authority to collect from States the data necessary for calculating such a rate.

In FY 2017, HHS reported that the improper payment rate exceeded 10 percent for the Medicaid program. In addition, two other programs that the Office of Management and Budget (OMB) has deemed susceptible to risk of improper payments (CHIP and Foster Care programs) did not meet their FY 2017 improper payment reduction target error rates (see TMC #3 for more information on reducing Medicaid improper payments).

Progress in Addressing the Challenge
In FY 2017, HHS awarded a 5-year contract for promoting and supporting innovation in TANF data, and one component of this contract is to help HHS and stakeholders better understand how States assess improper payments and ensure program integrity. This assessment will help HHS understand existing State and alternative approaches to estimating improper payments for TANF. CMS’s various corrective action efforts brought the Medicare FFS program into compliance with IPIA, resulting in reporting an improper payment estimate of less than 10 percent for the first time in several years. In the case of Medicaid, CMS continues working with the States to develop State-specific corrective action plans. CMS also shared Medicare data to assist States with meeting Medicaid screening and enrollment requirements and provided ongoing guidance, education, and outreach. CMS also offered training, technical assistance, and additional support to improve States’ Medicaid program integrity (see TMC #3 for more information on reducing Medicaid improper payments).

What Needs To Be Done
➢ HHS must continue to pursue needed legislative remedies to develop an appropriate methodology for measuring TANF payment accuracy and report an improper payment estimate for TANF.
➢ HHS should address and reduce improper payments in the Medicaid program.
➢ HHS must continue to establish and meet improper payments reduction targets, and report improper payments of less than 10 percent for all programs.
Improving contract management

Key Components of the Challenge
HHS is the fourth largest contracting agency in the Federal Government. In FY 2017, HHS awarded more than $24 billion in contracts across all program areas. These contracts can often have complex strategies involving multiple contractors, making them difficult to manage. Given the high dollar amounts and complexity of its contracts, it is paramount that HHS have strong monitoring and oversight.

However, challenges to the contract systems remain. OIG has identified vulnerabilities in acquisition planning and procurement and contract monitoring. For instance, key HHS contracts may not always undergo Contract Review Board oversight before being awarded, and when awarding contracts, CMS has not always performed thorough reviews of contractors’ past performance.

OIG has also raised issues regarding payments to contractors and contract closeouts. In the past, CMS and other agencies have frequently chosen contract types that place the risk of cost increases solely on the Government. Large backlogs of unclosed contracts can pose a significant financial risk to HHS. Finally, HHS has faced obstacles in the oversight and performance measurement of its benefit integrity contractors, which sometimes have substantial differences in the number of investigations initiated and cases referred to law enforcement.

Progress in Addressing the Challenge
HHS has taken steps to enhance its acquisition systems and better monitor contract closeouts and contract payments. CMS’s Office of Acquisition and Grants Management (OAGM) has increased productivity on its current backlog and implemented a quarterly closeout report that collects and monitors closeout data from each division. Additionally, CMS has improved the functionality of its Comprehensive Acquisition Management System to better track vendor invoicing.

CMS has also increased its efforts in examining workload statistics for benefit integrity contractors and improving performance outcomes. New investigations in program integrity priority areas (including home health, hospice, and laboratory services) increased from 18 to 25 percent from 2015 to 2016. The percentage of payment suspensions associated with the priority areas increased from 48 to 58 percent during that same time.

What Needs To Be Done
- To reduce vulnerabilities in acquisition planning and procurement, HHS should take steps to ensure that acquisition strategies are completed as required.
- Awarding agencies should assign systems integrators to complex contracts whenever appropriate, and CMS should ensure that its contracts undergo Contract Review Board oversight prior to being awarded.
- HHS must continue to strengthen its contracts oversight to assist in contract closeout and funds management.
- HHS can take further steps to improve coordination and collaboration across departmental staff with contract closeout responsibilities by, for example, establishing and maintaining guidelines for the division of work.
Implementing the DATA Act

Key Components of the Challenge
*The Digital Accountability and Transparency Act of 2014* (DATA Act) required OMB and the Department of the Treasury to establish government-wide data standards for reporting financial and payment information by May 2015. Broadly, the DATA Act required that HHS begin using the government-wide data standards to enter information into USASpending.gov by May 2017 to ultimately increase transparency and accountability. The DATA Act also required the Inspector General of each agency to determine the accuracy, completeness, timeliness, and quality of this data. For FY 2017, OIG’s audit of compliance with the DATA Act found that HHS complied with data standards established by OMB and the Department of the Treasury and entered the required information into USASpending.gov within the established timeframe. However, OIG found HHS relied on a manual and excessively labor-intensive process to comply with the government-wide data standards and continues to experience issues, as described above, with the information systems that support this data.

Progress in Addressing the Challenge
For FY 2017, HHS met the requirements for data accuracy, completeness, timeliness, and quality as well as complied with the reporting timeline established in the DATA Act.

What Needs To Be Done
- HHS must continue to address the weaknesses in its key financial management systems as described above and limit the need to rely on manual processes to submit the required data.

Key OIG resources
- *CMS Has Not Performed Required Closeouts of Contracts Worth Billions (OEI-03-12-00680)*, December 2015.
7. Protecting the Integrity of HHS Grants

**Why This Is a Challenge**
In FY 2017, HHS awarded $101 billion in grants (excluding CMS). HHS has increasingly used grant programs to address a variety of public health needs and crises, including the opioid epidemic, emergency preparedness, and natural disaster relief efforts (see TMCs #1 and #12 for more information on these grants). This expansion comes with an increased need to effectively manage grant funding. The growth of Federal funding to State and local governments also requires additional verification of existing controls and reporting requirements.

**Key Components of the Challenge**
- Ensuring appropriate and effective use of grant funds
- Ensuring effective grant management at the department level
- Ensuring program integrity and financial capability at the grantee level
- Combating fraud, waste, and abuse

**Ensuring appropriate and effective use of grant funds**

**Key Components of the Challenge**
Administering grant programs requires implementing internal controls to help ensure that program goals are met and funds are used appropriately. This includes oversight of both recipients and sub-recipients. Otherwise, funds can be misspent, duplication of services can occur, and sub-recipients may not be adequately monitored. Grant files must also be kept in an organized, accessible manner, which allows auditors and third-party reviewers to assess program appropriateness and effectiveness in a comprehensive, streamlined manner. OIG consistently identifies fraud and improper payments in the CCDF program.

**Progress in Addressing the Challenge**
HHS has begun its ReInvent Grants Management initiative as part of ReImagine HHS, a department-wide effort to evaluate how to best perform its mission. This initiative’s goal is to re-engineer the entire grant lifecycle to eliminate duplication and waste, and to reduce grantee burden. As part of this initiative, HHS has promoted enhancing performance measurements during application, award, and management processes. The Department is planning to develop analytical methods to allow better assessments of impact and value-based grant funding. HHS has also worked to provide quality assurance guidance to grantees. HRSA, for example, provided more specific guidance to grantees regarding the focus of their quality assurance programs and how they should conduct periodic assessments.

**What Needs To Be Done**
- HHS must maintain transparency and accountability for Federal funds. This includes ensuring that all HHS agencies maintain official files in accordance with HHS policy.
- Grant programs will need to effectively set baseline expectations and incentivize improvement.
- HHS should also issue an updated Grants Policy Statement that references the Part 75 grant rules and reflects the changes made by that rule.
- HHS must examine States’ methods for ensuring that sub-recipients of CCDF funds are adequately performing program integrity activities.
- When necessary, HHS should expand the scope of its State reviews to ensure that compliance with States’ CCDF plans are sufficiently assessed.
Ensuring effective grant management at the departmental level

Key Components of the Challenge
HHS is responsible for providing infrastructure for overseeing grants across the Department. Information must be effectively shared across grant programs to both correct for grant-awarding systems that do not interface and prevent the potential duplication of grant missions and funding. To fulfill this responsibility, HHS must collect and maintain timely, accurate, and complete data on grants programs. HHS should also implement OIG recommendations in a timely manner, which will ensure that Federal funds are effectively and efficiently used to carry out only the activities for which they are authorized.

Progress in Addressing the Challenge
In implementing its ReInvent Grants Management initiative, HHS has indicated a move towards outcome-based performance management in its grant process.

HHS is taking steps toward improving the interoperability of its IT systems. The HHS Office of the Assistant Secretary for Financial Resources (ASFR) has conducted an analysis to plan the implementation and usage of integrated databases that contain grantees’ past performance data, which will help promote transparency and accountability. In its ReInvent Grants Management initiative, HHS has begun implementing plans to develop a single platform that would streamline data entry and management and align shared services grant systems.

ASFR has taken steps to increase department-wide coordination. For instance, it has taken steps to facilitate department-wide information-sharing regarding grantees with past performance issues, which could help identify and prevent duplicative payments in the future. Additionally, on October 1, 2018, the Department launched the HHS Audit Tracking and Analysis System (ATAS). The system was primarily designed to systematically automate the assignment of Single Audit findings. The implementation of ATAS supports the Department and operating divisions in the timely resolution of Single Audit findings, intra-Department visibility of these findings, and identification of potential grantee risks across operating divisions.

What Needs To Be Done
- In implementing its new initiative, the Department will need to set appropriate measurement standards, monitor outcomes, and oversee program integrity.
- HHS must use ASFR’s ongoing analysis to guide the full implementation of interoperable grant management systems.
- HHS agencies should continue to use data and technology to improve grant system management.
- HRSA can develop additional data processes that work across the grant management lifecycle to reduce the elevated financial risks of health centers.
Ensuring program integrity and financial capability at the grantee level

Key Components of the Challenge
In managing its many grant programs, HHS is responsible for providing up-to-date policies to grantees, along with addressing States’ and other grantees’ inadequate financial management and internal controls. OIG has identified grantee-level concerns in many HHS programs, including some UAC program grantees reporting unallowable costs and lacking effective systems for administering program funds; States not sufficiently overseeing their CCDF program payments; and Head Start grantees not properly addressing audit findings. HHS also must hold States accountable to complying with the activities they outline in their specific State plans.

Progress in Addressing the Challenge
HHS has taken steps to improve its outreach and training on financial risk assessments for grant programs. The Department is providing information to HHS operating divisions on risk assessments, which they have used to update their policies. HRSA, for example, has updated its risk management process incorporating OIG input. Recently, NIH announced an increased effort to protect the integrity of U.S. biomedical research by partnering with NIH-funded academic institutions, relevant Government agencies, and other stakeholders. The initiative focuses on improving accurate reporting, mitigating risk to intellectual property security, and protecting the integrity of peer review. Furthermore, HHS also continues to conduct provider record reviews and onsite visits. For the CCDF program, States participating in site visits complete a self-assessment on fiscal responsibilities that identifies risks and issues related to program payments, as well as mitigation steps to improve practices. ACF has also implemented a new monitoring process for CCDF to help assess compliance with activities reported in State CCDF plans.

What Needs To Be Done
➢ HHS awarding agencies should work with States and other grantees to assess and strengthen their program integrity and program evaluation tools. For example, ACF should provide training for Head Start grantees on how to implement corrective action plans and take steps to resolve recurring Head Start Single Audit findings.
➢ HHS should help increase States and other grantees’ fraud-fighting efforts. HRSA, for example, should continue to explore additional steps that it could take to help health centers reduce their elevated financial risk.

Combatting fraud, waste, and abuse

Key Components of the Challenge
HHS faces persistent and heightened challenges in preventing fraud in its grant programs. Without sufficient grantee oversight and internal controls, grants are vulnerable to fraud schemes, including embezzlement.

Progress in Addressing the Challenge
HHS has worked to increase its employees’ knowledge of and effectiveness in combatting fraud. For instance, it has collaborated with OIG on training opportunities, including the OIG 2018 Grants Forum, that have focused on topics related to fraud, including suspension and disbarment and how to report potential fraud, waste, and abuse.
HHS has also worked to strengthen some program integrity efforts. For instance, it issued guidance to HHS awarding agencies about facilitating a review of prospective grantees prior to awarding grants. This information enhances awarding agencies’ assessment of prospective grant recipients’ integrity and potential performance. In addition, the Federal Awardee Performance and Integrity Information System database includes information—such as contractor criminal, civil, and administrative proceedings related to Federal awards, and suspensions and debarments—that will improve HHS’s access to information pertaining to contractor misconduct and performance.

Further, HHS awarding agencies have begun reaching out to OIG regarding allegations of fraud. For example, HRSA officials referred allegations to OIG that resulted in significant criminal convictions and recoveries on behalf of HRSA’s grant program and shut down a fraud scheme in which Federal funds were being stolen and diverted for personal use.

**What Needs To Be Done**

- HHS grant programs, grantees, and sub-recipients, in collaboration with OIG, must work to recognize the prevalent fraud schemes and regularly engage in antifraud activities, including reviewing provider records for potential fraud, identifying duplicate payments, performing verification checks, and conducting onsite visits.
- Once identified, HHS, grantees, and grant sub-recipients must continue to refer suspected fraud to OIG.
- All HHS agencies with grant programs should work to increase their number of referrals each year. This collaboration and referrals will allow for the full use of all available enforcement remedies—criminal, civil, and administrative—when fraud, waste, or abuse is identified.

**Key OIG resources**

- *Not All of Missouri’s Child Care Subsidy Program Payments Complied with Federal and State Requirements (A-07-1504226)*, November 2017.
- *More Effort Is Needed to Protect the Integrity of the Child Care and Development Fund Block Grant Program (OEI-03-16-00150)*, July 2016.
8. Ensuring the Safety of Food, Drugs, and Medical Devices

Why This Is a Challenge
FDA has the continuing challenge of ensuring the safety and security of the Nation’s food and medical products (including drugs, biological products, and medical devices), which directly affect the health of every American. With an annual budget of more than $5 billion, FDA oversees products that represent about 20 percent of all U.S. consumer spending. FDA has a broad statutory mandate that has continued to expand through recent legislation. The Cures Act, for instance, provided new authorities to help spur medical innovation and modernize medical product regulation throughout a product’s lifecycle.

Ensuring food safety

Key Components of the Challenge
- Ensuring food safety
- Ensuring the safety, effectiveness, and quality of drugs and medical devices
- Ensuring the security of drug supply chains

Key Components of the Challenge

Ensuring food safety
Each year roughly 48 million people get sick from a foodborne illness, 128,000 are hospitalized, and 3,000 die.20 FDA inspects food facilities to ensure food safety and compliance with regulations. Various administrative tools and enforcement authorities can be used to protect the public from unsafe food. However, FDA faces challenges in ensuring that inspections of domestic food facilities are conducted in a timely manner and that significant inspection violations are corrected. FDA has not always used its full enforcement authorities and faces obstacles in maintaining an efficient and effective food recall process.

Progress in Addressing the Challenge
FDA is currently on track to meet the domestic food facility inspection timeframes for the initial cycles mandated by the Food Safety Modernization Act. It has also initiated a new food recall quality system audit process and has developed a plan to provide early notice to the public. FDA also established the Strategic Coordinated Oversight of Recall Execution (SCORE) initiative, a team of FDA senior leaders that examines cases that present significant hazards to human health and makes decisions pertaining to challenging high-risk food-recall cases.

What Needs To Be Done
- FDA should work to keep the food supply safe by creating a process for timely, effective corrections of problems identified during domestic food facility inspections.
- FDA should take appropriate actions against all food facilities with significant inspection violations.
- Procedures should also be in place to guarantee that food recalls are initiated promptly. For example, FDA should use its SCORE initiative to establish set timeframes, expedite decision making and move recall cases forward, and improve electronic recall data.

---

Ensuring the safety, effectiveness, and quality of drugs and medical devices

Key Components of the Challenge
FDA’s responsibility to ensure safe and effective medical devices begins before a device is brought to market and continues after FDA approval. This includes overseeing facilities; reviewing drugs, devices, and biologics for safety and efficacy; authorizing the use of investigational medical products; and conducting postmarket surveillance. FDA oversees more than 8,500 drug facilities and 21,000 medical device facilities, and in 2017, FDA approved 56 novel drugs and biologics, 80 first-time generic drugs, 5 biosimilars, and 95 novel medical devices. FDA, in partnership with State authorities, also oversees compounded drugs, which are not subject to FDA’s premarket process. It continues to identify issues with the development of compounded drugs.

FDA must make sure that medical devices remain safe and retain an acceptable quality after they have entered the market. This involves adapting to changing technology and reviewing many factors both pre- and post-market release, including any potential cybersecurity threats to medical devices.

Cybersecurity of medical devices is increasingly important for patients’ safety and health. With devices increasingly dependent on software and Internet access, procedures to address cybersecurity risks before and after a device is cleared or approved are essential.

Progress in Addressing the Challenge
FDA has worked to implement the tools provided by Congress in the Cures Act to help promote the development of safe and effective medical devices. For example, in December 2016 FDA established the Regenerative Medicine Advanced Therapy designation program as authorized in the Cures Act. Since the RMAT program inception, 24 RMAT Designations have been granted as of June 30, 2018. This program is intended to facilitate efficient development, and expedite review, of certain regenerative medicine therapies for serious conditions through, among other things, early and frequent interactions between FDA and product sponsors.

FDA has improved how it conducts its inspections and reviews. For example, it has increased capacity for inspecting generic drug manufacturers by finalizing its policies and procedures for requesting records in lieu of or in advance of an inspection. Additionally, FDA has increased its efforts to address cybersecurity as part of the pre-market review process. For example, FDA issued guidance on device submissions and cybersecurity in October 2014, which it uses to assist its cybersecurity review. On October 17, 2018, FDA updated its guidance to better help ensure device manufacturers are adequately addressing evolving cybersecurity threats.21

FDA has also taken steps to hold drug manufacturers accountable for satisfying regulatory requirements. For instance, it has improved its ability to hold drug manufacturers accountable for fulfilling REMS requirements by identifying and following up on incomplete assessments. For devices, FDA has prioritized development of active surveillance through continuing to build out the National Evaluation System for Health Technology (NEST) which uses real-world evidence to evaluate premarket and postmarket safety, reducing the time and cost of innovative device development, fostering reimbursement, and providing greater patient safeguards at a lower cost.

What Needs To Be Done

- FDA must continue to ensure timely implementation of the statutory authority granted in the Cures Act. FDA must also continue to take additional steps to improve both the premarket review process and its procedures for responding to postmarket cybersecurity incidents. This should include further integration of cybersecurity assessments into FDA’s processes.
- FDA is encouraging device manufacturers to consider cybersecurity risks and implement controls as they create and develop each device to help mitigate potential cybersecurity threats. In addition, FDA should promote the use of early meetings between FDA and device manufacturers to discuss specific cybersecurity questions that manufacturers need to address prior to submitting a device application to FDA.
- FDA should include cybersecurity documentation (such as a threat modeling and cybersecurity risk assessment) as part of the hazard analysis describing a device’s cybersecurity risks and controls that a manufacturer has considered, in information that manufacturers are required to submit to FDA for its premarket review.

Ensuring the security of the drug supply chain

Key Components of the Challenge
Drug supply chains continue to grow increasingly complex in both domestic and global markets. As a result, intricate supply chains present FDA with many challenges as drugs face risks of diversion, theft, counterfeiting, and adulteration. This makes open communication and exchange of necessary information even more important. To enhance drug supply chain security, the Drug Supply Chain Security Act (DSCSA) requires trading partners in the drug supply chain to exchange certain information in each drug product transaction and to identify and investigate suspect and illegitimate products. It is therefore expected that the exchange of complete information among trading partners in the drug supply chain will facilitate FDA’s investigations, identify harmful medical products, prevent further distribution of adulterated products, and facilitate efficient recalls.

Progress in Addressing the Challenge
Trading partners in the drug supply chain have been exchanging drug product tracing information in each transaction since the requirements to do so took effect in 2015. OIG has found that roughly one-half of wholesalers, including those representing the vast majority of transactions, exchange everything required by FDA. These companies have also developed a variety of methods for exchanging the necessary information. OIG has also found that dispensers are moving toward full implementation of the DSCSA requirements, but that some dispensers may still be unaware of the DSCSA or lack an understanding of their drug product tracing responsibilities.

What Needs To Be Done

- FDA needs to offer more educational and technical assistance to drug wholesale distributors and dispensers on how to best implement the drug product tracing provision of the DSCSA.

---

22 Drug Quality and Security Act, P.L. No.113-54, Title II.
Key OIG resources

- *The Food and Drug Administration Food-Recall Process Did Not Always Ensure the Safety of the Nation’s Food Supply (A-01-11-601502), December 2017.*
- *Drug Supply Chain Security: Dispensers Received Most Tracing Information (OEI-05-16-00550), March 2018.*
Ensuring Quality and Integrity in Programs Serving American Indian/Alaska Native Populations

**Why This Is a Challenge**

Many HHS programs provide health and human services to AI/ANs throughout the U.S., with IHS directing the largest amount of targeted funding to AI/AN communities. With a budget of $5.5 billion in FY 2018, IHS is responsible for providing primary and preventive health services to 2.3 million AI/ANs in partnership with the 573 federally recognized Tribes. Other HHS agencies provide grants to Tribes for human services programs, including Head Start and the Low-Income Home Energy Assistance Program (LIHEAP).

HHS faces significant challenges to ensuring effective delivery of crucial services to AI/AN communities and protecting funds from fraud, waste, and abuse. The AI/AN population historically has had disparate health outcomes compared to the rest of the U.S. population. There have been some important health improvements among the AI/AN population over the past two decades, such as reduced mortality rates from tuberculosis and heart disease, among others. Even with these improvements, AI/ANs continue to face numerous health disparities in comparison to the national population. For instance, the infant mortality rate for AI/ANs is about 25 percent higher than the national rate, and AI/ANs are almost twice as likely as the overall population to have diabetes. AI/AN populations also have disproportionately high rates of suicide, unintentional injuries resulting in death, and drug overdose deaths *(see TMC #1 for more information on IHS challenges and progress specific to opioid misuse)*. Many AI/AN communities are in geographically remote locations, adding to the operational and management challenges of the HHS programs that serve them.

**Key Components of the Challenge**

- Addressing deficiencies in IHS management, infrastructure, and quality of care
- Preventing fraud and misuse of HHS funds serving AI/AN populations

**Addressing deficiencies in IHS management, infrastructure, and quality of care**

During the past 3 years, Medicare compliance deficiencies affected patient care at 3 of the 25 IHS-operated hospitals. Two hospitals lost their Medicare certification and a third closed its emergency departments for 7 months in 2016. These deficiencies have a direct and detrimental effect on patient care and relate to several longstanding challenges. IHS faces difficulties in recruiting and retaining essential staff and in maintaining its staff’s clinical competency in low-volume hospitals. Healthcare services are provided in remote locations, often in outdated buildings and using old equipment. Compounding these problems, the Purchased and Referred Care program, intended to supplement IHS services by purchasing select services from non-IHS providers, faces financial shortfalls in at least some Areas every year. When this happens, IHS prioritizes the most acutely urgent requests and some AI/ANs go without preventive services, primary and secondary care, and other services. Additionally, OIG found that some IHS hospitals have deficiencies in their continuity of operations programs and disaster recovery plans and were unable to retrieve patients’ records in the event of physical damage. While most of OIG’s work has focused on IHS-run facilities, OIG also found that one tribally run health center in Maine did not always have a physician who provided medical direction, clear lines of authority and
responsibility between medical and administrative decisionmaking, and medical policies and procedures.

OIG found that IHS headquarters and Area offices do not provide sufficient oversight of the quality of care provided in IHS facilities. Area offices have a complaints and patient harm reports problem. Additionally, most area offices depend on infrequent Governing Board meetings to review quality metrics.

**Progress in Addressing the Challenge**

IHS is working to implement a broad quality framework with several initiatives to improve the care provided in its hospitals and clinics. These initiatives include developing a quality dashboard to track compliance and quality efforts, adopting new standards for hospital governing boards, and acquiring a new credentialing software system to ensure that providers have necessary qualifications. IHS is also pursuing expanded access for AI/AN services through new telehealth contracts and heightened standards for patient appointment-setting and wait times. IHS also awarded a contract to the Joint Commission for accreditation, training, and education to strengthen quality and patient safety. Supporting these efforts for IHS hospitals that participate in Medicare, CMS committed to conducting more frequent surveys of non-accredited IHS hospitals and is assisting with quality improvement efforts in IHS facilities through its Quality Improvement Network, Quality Improvement Organization (QIO), and Hospital Engagement Network programs.

**What Needs To Be Done**

- To improve quality of care and patient safety, HHS should reconvene a multi-agency council focused on overcoming the longstanding challenges to providing high quality care to AI/AN populations.
- IHS should develop and implement a comprehensive quality-focused compliance program for IHS hospitals.
- IHS should implement an agency-wide strategic plan with actionable initiatives and target dates.
- CMS should continue to communicate with IHS leadership about deficiencies in IHS facilities citations and continue to provide technical assistance and training to IHS hospitals in the QIO 11th Scope of Work.
- IHS should offer technical assistance to Tribes that operate their own clinics pursuant to the Indian Self-Determination and Education Assistance Act. This should include assistance to Tribes that operate health centers enrolled as Medicare Federally Qualified Health Centers to help Tribes ensure that their health centers are under the medical direction of a physician; establish clear lines of authority and responsibility between medical and administrative decisionmaking; and develop and implement medical policies and procedures to comply with health and safety requirements.
- To better protect patient information and continuity of operations for IHS hospitals, IHS should test mechanisms at all IHS hospitals to ensure patient information is fully recoverable and implement an effective continuity of operations program and disaster recovery plan and procedures in accordance with Federal requirements.
**Preventing fraud and misuse of HHS funds serving AI/AN populations**

**Key Components of the Challenge**
OIG has found fraud and misuse of HHS funds in serving AI/AN populations and has performed audits and taken legal action. OIG has found that some Tribes and Tribal organizations have not adequately protected funds under the Indian Self-Determination and Education Assistance Act and other programs, resulting in embezzlement and theft of Federal funds. OIG has also enforced Civil Monetary Penalty (CMP) Law to reclaim funds from organizations in violation. OIG has also identified improper administration of funds by Tribes in the Indian Self-Determination and Education Assistance Act program and LIHEAP. Errors included, among others, failure to adequately track and support payments and failure to refund unobligated funds as required because the Tribes we audited did not have policies and procedures or internal controls to prevent these issues.

**Progress in Addressing the Challenge**
In May 2018, OIG led 2 days of compliance training for 250 IHS and Tribal employees and other stakeholders on internal controls, compliance programs, and ensuring quality care. OIG staff also made presentations to AI/AN audiences about compliance at four additional conferences led by HHS agencies and Tribal members.

OIG has taken multiple actions to prevent the misuse of Federal funding serving AI/AN populations. For example, OIG has enforced CMPs against Tribes and entered into settlement agreements for improperly billing Federal healthcare programs. OIG has identified improper payments at a tribal health clinic funded by IHS and in two Tribal LIHEAP programs. Additionally, OIG entered into a False Claims Act voluntary compliance agreement with a Tribe that improperly billed Medicaid, and has assisted DOJ in prosecuting Tribal employees who embezzled HHS funds.

**What Needs To Be Done**
- HHS agencies should continue to collaborate on strengthening program integrity and safeguarding HHS funds intended to serve AI/AN populations.
- OIG will continue to promote coordination and will expand oversight of HHS programs serving AI/ANs by conducting audits alongside OIGs from other departments serving these communities. Tribes and Tribal organizations can contribute to these goals by implementing strong internal control mechanisms and training staff on compliance and proper procedures, such as adherence to OMB cost principles when using Indian Self-Determination and Education Assistance Act funds.
Key OIG resources

- Protecting Indian Health and Human Services Programs and Their Beneficiaries: The Basics of Health Care and Grants Management Compliance (OIG 2018 Conference), May 2018.
- The Indian Health Service Did Not Always Resolve Audit Recommendations in Accordance With Federal Requirements (A-07-17-03227), September 2018.
- The Passamaquoddy Tribe’s Pleasant Point Health Center Did Not Always Meet Federal and Tribal Health and Safety Requirements (A-01-11-701500), July 2018.
- Two Indian Health Service Hospitals Had System Security and Physical Controls for Prescription Drug and Opioid Dispensing but Could Still Improve Controls (A-18-16-30540), November 2017.
- Expenses Incurred by the Rocky Boy Health Board Were Not Always Allowable or Adequately Supported (A-07-15-04221), March 2016.
- Indian Health Service Hospitals: More Monitoring Needed to Ensure Quality Care (OEI-06-14-00010) and Indian Health Service Hospitals: Longstanding Challenges Warrant Focused Attention to Support Quality Care (OEI-06-14-00011), October 2016.
10. Protecting HHS Data, Systems, and Beneficiaries from Cybersecurity Threats

Why This Is a Challenge
Data management, use, and security are essential to the effective and efficient operation across HHS’s agencies and programs. Each agency has its own mission, budget, leadership, and IT systems. HHS spends more than $5 billion every year on IT (not including grants-related IT expenditures). The environment in which HHS must protect its systems is complex, with ever-increasing volumes of data residing in many places and with many entities and individuals, and with continued expansion of the Internet of Things, including networked medical devices. Those possessing health and human services data—including public stakeholders—have cybersecurity responsibilities, which include ensuring effective people, processes, and technologies are in place to protect HHS data. The Department’s challenges are, thus, multifaceted and include protecting data on internal systems, overseeing the cybersecurity of data in cloud environments, and ensuring that providers, grantees, and contractors are adhering to sound cybersecurity principles.

Among HHS operating divisions, CMS is the single largest payer for healthcare in the U.S. The integrity of IT systems used to operate the $900+ billion in programs administered by CMS is thus critically important to the health and well-being of the American people. Oversight of the integrity of State Medicaid and MCO IT systems is also under HHS’s jurisdiction. Moreover, the IT systems at FDA, IHS, and other HHS agencies present qualitatively different types of cybersecurity challenges. FDA, for example, is charged with regulating the safety, effectiveness, and security of food, cosmetics, drugs, biological products, and medical devices (see TMC #8 for more information on challenges specific to safety of food, drugs, and medical products). By contrast, IHS is responsible for providing Federal health services to AI/ANs. FDA’s IT systems process and maintain data that looks very different from that of IHS and other agencies. The cybersecurity of IHS systems will continue to remain a focus for OIG, as confidentiality, integrity, and availability of IHS healthcare systems is linked to improving care and patient safety.

The cybersecurity threats facing HHS are real and pressing. Healthcare data is a prime target for cybercriminals, and the value of a compromised EHR has been reported to be as much as 10 times that of a credit card number. In addition to identity threats, compromising the integrity and availability of HHS systems can adversely affect patient care. The WannaCry ransomware vulnerability, for example, affected an estimated 300,000 computers world-wide and resulted in thousands of operations and appointments being canceled unless ransoms of $300 to $600 were paid per malware instance. The Department has employed measures to notify hospitals about how to mitigate the impact of this vulnerability to the U.S. healthcare system.

Securing HHS’s data and systems

Key Components of the Challenge
The infinite number of threats in cyberspace makes it nearly impossible to prevent every attack that looms on the horizon. As more healthcare functions come online (e.g., the healthcare Internet of Things, telemedicine, etc.), HHS will have to address new types of cybersecurity challenges. Any doubts
that the public may have about HHS’s ability to protect confidential, personal health data may hinder the full potential of Federal initiatives (e.g., NIH’s All of Us Research Program) that seek to leverage technology to create medical treatments of the future. HHS lacks robust resources to comprehensively prepare cybersecurity personnel (i.e., to test the different types of incident responses and recovery procedures that may reveal gaps) to respond efficiently and effectively when an actual attack occurs.

**Progress in Addressing the Challenge**

The 2017 HHS budget allocated $50 million to meet HHS’s cybersecurity needs and to ensure that HHS could protect sensitive and critical information. HHS has implemented continuous monitoring tools to facilitate security compliance and has partnered with a commercial vendor to deploy threat hunting technologies at some HHS agencies. Security awareness and phishing prevention campaigns are instituted throughout the year. Continuous dialogue takes place across HHS agencies, focusing on cybersecurity and operational challenges. Select HHS agencies also coordinate with DHS to conduct cybersecurity testing. HHS is using a standardized log-analysis platform that will enable HHS and its operating divisions to better perform deep analysis of events and facilitate automation and integration with internal and external data sources and security tools. In addition, DHS conducts security scans of external-facing HHS systems. To help ensure the resilience of HHS systems, the Secretary signed a memorandum on April 5, 2018, informing all HHS agency leadership that entities within HHS would be responsible for planning and establishing necessary capabilities and being prepared to perform their respective Mission Essential Functions, with little or no warning and under any operating conditions. OIG continues to assess HHS cybersecurity vulnerabilities.

**What Needs To Be Done**

- A well-designed contingency program should be in place not only to respond to natural or man-made disasters but also as a key feature of cyber-defenses.
- Similarly, HHS must be proactive in identifying vulnerabilities and developing mitigation protocols in a timely manner to combat current and future cybersecurity threats. HHS should therefore focus on its capabilities to respond efficiently and effectively to a wide range of threats to healthcare and the resilience of its information systems, including its incident response coordination channels and contingency planning.
- To protect its data and systems, the Department must continue to take steps to address vulnerabilities previously identified by OIG and others.

**Advancing cybersecurity within the healthcare ecosystem**

**Key Components of the Challenge**

Information sharing is one of the most effective tools in the cybersecurity defense toolbox. The U.S. mitigated the effects of the WannaCry vulnerability largely because public and private sector entities shared information with stakeholders in real time. Within hours of the attack spreading through Europe, HHS notified its agencies and private sector entities about the attack. So, while cyber-attacks are nearly impossible to predict, once they occur, it is possible to obtain and share needed information with public and private partners, including how and where the exploit occurred, what types of systems are under attack, and, most important, what steps may be taken to mitigate the threat. HHS must continue to be at the forefront in encouraging cybersecurity information sharing and coordination among the healthcare public and private sectors. Because Government, academia, and private industry often employ similar technologies in providing healthcare and conducting medical research, there is great value in sharing cybersecurity vulnerabilities within commonly used systems.
Progress in Addressing the Challenge

The Department and its public and private partners and stakeholders have taken some steps to address coordination and information sharing concerning cybersecurity threats, but they must continue to work to enhance capabilities. Health-care-specific cybersecurity information sharing and analysis reports are available through numerous sources, including FireEye iSight reports, National Health Information Sharing and Analysis Center, Health Sector Cybersecurity Coordination Center, and the Computer Security Information Response Center. Some HHS agencies have created memoranda of understanding with outside information sharing organizations to better coordinate cybersecurity efforts. The FDA Commissioner announced a CyberMed Safety Analysis Board, a public-private entity composed of representatives from Government, academia, and industry to fully assess and validate high-risk medical device vulnerabilities and incidents.

What Needs To Be Done

- HHS agencies should continually seek opportunities to partner with other Government agencies, private industry, academia, and State Governments to share information on cybersecurity, emerging threats, risks, and best practices.
- HHS must continue to engage the healthcare and public health sectors to ensure that cybersecurity threats are properly communicated and that appropriate guidance on foundational cyber hygiene best practices is available. Both help protect the sector and, in turn, the HHS environment.

Key OIG resources

11. Ensuring that HHS Prescription Drug Programs Work as Intended

Why This Is a Challenge
HHS programs accounted for almost 40 percent ($130 billion) of the total U.S. prescription drug expenditures in 2016. HHS oversees coverage of prescription drugs under various programs operated by the Department, such as Medicare, Medicaid, and IHS. In addition to providing drug coverage benefits through CMS and IHS, the Department also impacts prescription drug availability and pricing through agencies such as FDA and HRSA’s 340B Drug Pricing Program.

Increases in drug prices have contributed to the growth in total prescription drug spending. Patients and Government programs may be overpaying for prescription drugs. Increases in drug prices may limit patients’ access to needed prescription drugs if the out-of-pocket costs become unaffordable. The Administration recognized this with its release of “American Patients First,” the President’s blueprint to lowering drug prices and reducing out-of-pocket costs. HHS is committed to increasing transparency to improve oversight of prescription drug payments and reimbursements.

Key Components of the Challenge
➢ Protecting the integrity of prescription drug programs
➢ Fostering prudent payments for prescription drugs
➢ Ensuring appropriate access to prescription drugs

Protecting the integrity of prescription drug programs

Key Components of the Challenge
To limit Medicaid expenditures for prescription drugs, Congress created the Medicaid Drug Rebate Program in 1990; CMS and States implemented the Program in 1991. However, it is a longstanding challenge to ensure that drug manufacturers and State Medicaid agencies are complying with requirements. OIG recently found that potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates.

HHS faces challenges in ensuring the integrity of the Medicare prescription drug programs. For instance, OIG has continued to raise concern about payments for expired drugs. In addition, OIG found that Part D spending for compounded topical drugs was 24 times higher in 2016 than in 2010, raising concerns about fraud and abuse.

OIG has identified two longstanding fundamental vulnerabilities in the 340B program: (1) a lack of transparency that prevents ensuring that 340B providers are not overpaying pharmaceutical manufacturers and that State Medicaid programs are not overpaying 340B providers, and (2) a lack of clarity regarding program rules that creates inconsistencies in how contract pharmacies implement the program.

**Progress in Addressing the Challenge**

States are now appropriately reporting offset rebate amounts on their Medicaid expenditure reports. CMS is monitoring this as part of the certification review at the close of each reporting period. CMS reports that the amount of offset rebates collected increased by $400 million because of these efforts.

Additionally, in August 2018, the Administration released guidance clarifying how drug rebates are computed for a “line extension” of an existing pharmaceutical manufacturer’s drug. The change intends to prevent manufacturers from treating new formulations of existing drugs as new medications to lower Medicaid rebate amounts owed to States. The Congressional Budget Office estimates that this change could save $6.5 billion over 10 years.²⁴

CMS has taken a number of compliance and enforcement actions against Medicare Part D plan sponsors. CMS has also continued to expand use of its Overutilization Monitoring System and released guidance for Part D plan sponsors to implement lock-in programs to prevent abuse of Part D drugs.

HRSA has taken steps to improve oversight of the 340B program and was granted additional oversight authorities. HRSA received authority to share 340B ceiling prices with 340B providers and was given new enforcement tools, including authority to impose CMPs for manufacturers that knowingly and intentionally overcharge 340B providers.

**What Needs To Be Done**

- CMS should pursue a means to compel manufacturers to correct inaccurate classification data reported to the Medicaid Drug Rebate Program. The methods could include, for example, seeking legislative authority to compel manufacturers to submit accurate data and/or enhance its enforcement authority.
- Although States are now appropriately reporting rebates to CMS, CMS did not always provide accurate Medicaid quarterly unit rebate offset amounts to State Medicaid agencies. The State agencies would have used incorrect unit rebate offset amounts to calculate rebates that were reported to CMS, which would have resulted in incorrect rebate amounts being claimed. CMS should conduct periodic matches that would compare unit rebate offset amount information sent to State agencies with the Medicaid drug rebate system.
- For a covered outpatient drug to be eligible for Federal reimbursement under Medicaid’s drug rebate requirements, manufacturers must participate in the Medicaid Drug Rebate program and pay rebates to the States for the drugs. State Agencies need to strengthen internal controls to ensure that all physician-administered drugs eligible for rebates are invoiced.
- OIG has recommended that Part D prescribers be required to enroll in Medicare for program integrity purposes. CMS recently established a preclusion list for problematic Part D prescribers that would prohibit Medicare payment for drugs prescribed by providers on this list. The list includes certain individuals and entities revoked from Medicare or those who have engaged in behavior for which CMS could have revoked the individual or entity if they had been enrolled in Medicare. OIG believes that requiring enrollment in Medicare would help ensure that only reputable and qualified individuals and entities are providing services to Medicare beneficiaries.
- CMS should require the use of claim-level methods to help States more accurately identify 340B drug claims, and thus reduce the risk of duplicate discounts and forgone rebates associated with

---

provider-level methods. CMS may need legislative authority to require States to use claim-level methods.

- HRSA should increase transparency by sharing 340B ceiling prices with 340B providers and States. HRSA may need new legislative authority to share 340B ceiling prices with States. HRSA should also clarify its guidance on preventing duplicate discounts for drugs paid through Medicaid MCOs.

- CMS should clarify Part D policies for coverage of compounded topical drugs and the use of utilization management tools. In addition, CMS should conduct training for Part D sponsors on fraud schemes and safety concerns related to compounded topical drugs.

### Fostering prudent payments for prescription drugs

**Key Components of the Challenge**

How CMS sets the amount reimbursed for a drug can result in additional costs for programs and their beneficiaries. For example, Medicare Part B would have saved millions of dollars if dispensing fees for inhalation drugs administered through DME and supplying fees for immunosuppressive drugs associated with an organ transplant, oral anticancer chemotherapeutic drugs, and oral antiemetic drugs used as part of an anticancer chemotherapeutic regimen had been aligned with the rates that Part D and State Medicaid programs paid. Additionally, CMS includes noncovered versions of drugs when calculating payment amounts for two Part B drugs, Orencia and Cimizia. The inclusion of these drugs caused Medicare and its beneficiaries to pay an extra $366 million from 2014 through 2016.

**Progress in Addressing the Challenge**

The Bipartisan Budget Act of 2015 established a requirement that manufacturers pay an additional rebate when the average manufacturer price (AMP) for a generic-name drug increases by more than a specified inflation factor. The additional rebate for generic drugs applies to rebate periods beginning with the first quarter of 2017. Additionally, legislative change requiring DME infusion drugs to be paid using the average sales price (ASP) methodology will save $660 million over 10 years. Lastly, CMS altered its payment methodology for 340B drugs in the Hospital Outpatient Prospective Payment System (OPPS) to save beneficiaries an estimated $320 million on copayments in 2018. Starting in 2019, CMS will allow Medicare Advantage plans to use new cost-saving and negotiation tools for Part B drugs. These tools are already successfully used in the Part D program.

**What Needs To Be Done**

- CMS should seek a legislative change that would provide the agency flexibility to determine when noncovered versions of a drug should be included in Medicare Part B payment amount calculations.

- CMS should amend current regulations to decrease the Medicare Part B payment rates for dispensing and supplying Part B drugs to rates similar to those of other payers, such as Medicare Part D or Medicaid.
Ensuring appropriate access to prescription drugs

Key Components of the Challenge
High drug prices can limit access to needed prescription drugs. For instance, OIG found that increasing prices for brand-name drugs may result in increasing costs for Medicare and its beneficiaries, especially those beneficiaries who need access to expensive drugs. Increases in drug prices may limit patients’ access to needed prescription drugs if the out-of-pocket costs become unaffordable.

Generic and biosimilar prescription drugs are important because they are often sold at lower prices and with lower patient payment obligations. Availability of generics and biosimilars can be an important mechanism for ensuring appropriate access to prescription drugs.

Progress in Addressing the Challenge
FDA announced a Drug Competition Action Plan to lower drug prices and increase access for patients by removing barriers to generic drug development and market entry. FDA, “Statement from FDA Commissioner Scott Gottlieb, M.D., on the Trump Administration’s plan to Lower Drug Prices,” May 2018. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607495.htm

The agency’s actions include publishing a list of off-patent, off-exclusivity drugs without approved generics and implementing a revised prioritization policy to expedite the review of generic drug applications until there are three approved generics for a given drug product. In 2017, FDA approved 1,027 new generic drugs, the highest number of generic drug applications in its history. FDA, “2017 Was Another Record-Setting Year for Generic Drugs,” February 2018. Available at: https://blogs.fda.gov/fdavoice/index.php/2018/02/2017-was-another-record-setting-year-for-generic-drugs/

To complement the Drug Competition Action Plan, FDA subsequently released a Biosimilars Action Plan to facilitate the efficient development and approval of biosimilars to increase competition in the biologics marketplace and thereby reduce costs. As of October 2018, FDA has approved 13 biosimilars, including biosimilars for the treatment of cancer. Under the 2019 Part C and Part D regulation issued by CMS, Medicare beneficiaries receiving low-income subsidies can access biosimilars with lower out-of-pocket costs.

CMS has acknowledged that action is necessary to address rising drug costs and asked the industry to partner with the agency to find solutions that allow for both innovation and affordability. CMS has taken regulatory steps to increase access for Medicare beneficiaries, including allowing for certain low-cost generic drugs to be substituted onto plan formularies at any point during the year so beneficiaries immediately benefit by lower cost-sharing for these drugs.

What Needs To Be Done
- When determining prudent payment policies and ensuring program integrity in HHS prescription drug programs, HHS should ensure appropriate access for beneficiaries. For instance, plans need to meet minimum access requirements when implementing their utilization management tools.

---

25 FDA, “Statement from FDA Commissioner Scott Gottlieb, M.D., on the Trump Administration’s plan to Lower Drug Prices,” May 2018. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607495.htm
26 FDA, “2017 Was Another Record-Setting Year for Generic Drugs,” February 2018. Available at: https://blogs.fda.gov/fdavoice/index.php/2018/02/2017-was-another-record-setting-year-for-generic-drugs/
Key OIG resources

- States’ Collection of Medicaid Rebates from Drug Manufacturers (OIG series of reports), February 2018.
- Potential Misclassifications Reported by Drug Manufacturers May Have Led to $1 Billion in Lost Medicaid Rebates (OEI-03-17-00100), December 2017.
- Questionable Billing for Compounded Topical Drugs in Medicare Part D (OEI-02-16-00440), August 2018.
- Examining Oversight Reports on the 340B Drug Pricing Program (OIG Testimony), May 2018.
- CMS Did Not Always Provide Accurate Medicaid Unit Rebate Offset Amounts to State Medicaid Agencies (A-07-17-06074), May 2018.
- Medicare Part B Prescription Drug Dispensing and Supplying Fee Payment Rates Are Considerably Higher Than the Rates Paid by Other Government Programs (A-06-12-00038), September 2014.
- Excluding Noncovered Versions When Setting Payment for Two Part B Drugs Would Have Resulted in Lower Drug Costs for Medicare and its Beneficiaries (OEI-12-17-00260), November 2017.
- Medicare Part B Prescription Drug Dispensing and Supplying Fee Payment Rates Are Considerably Higher Than the Rates Paid by Other Government Programs (A-06-12-00038), September 2014.
- Increases in Reimbursement for Brand-Name Drugs in Part D (OEI-03-15-00080), June 2018.
- The MEDIC Produced Some Positive Results but More Could be Done to Enhance its Effectiveness (OEI-03-17-00310), July 2018.
12. Ensuring Effective Preparation and Response to Public Health Emergencies

Why This Is a Challenge
Public health emergencies, such as emerging infectious diseases and natural disasters, can severely strain public health and medical infrastructure and lead to serious illness and loss of life. As the lead agency for the Federal response to public health emergencies, HHS is responsible for ensuring both it and its State and local partners are prepared to respond to, and recover from, public health emergencies efficiently and effectively.

During a disaster response, Federal, State, and local entities must collaborate to provide response and recovery services. However, this often leads to challenges with coordination and information sharing within and across these entities.

Ensuring access to health and human services during and after emergencies

Key Components of the Challenge
During and after a public health emergency, State and local governments must ensure they have adequate plans (such as preparing for a medical surge) and mechanisms in place to efficiently and rapidly deploy assets and provide relief to those in need. For example, the destruction from the 2017 hurricane season left many individuals without medical care, including in facilities without electricity, and other needed health and human services resources in the immediate aftermath and for subsequent months. State and local governments must also coordinate with healthcare facilities and other entities to leverage resources during a response.

Prior OIG work has identified gaps in emergency preparedness and response planning and community preparedness for healthcare facilities during disasters and pandemics. For example, OIG found that many hospitals and other entities in disaster areas affected by Superstorm Sandy encountered problems with distributing shared resources, such as hospital beds and access to fuel and transportation, which decreased hospitals’ capability to care for patients. OIG has also historically identified gaps in nursing home emergency planning, disaster response, and coordination with State and local entities. Nursing homes often struggle to execute emergency plans and protect residents after disasters hit, despite receiving enhanced guidance from CMS. For example, during the 2017 hurricane season, reports of nursing homes’ performance found failures to evacuate residents or provide safe sheltering in place, which raises questions about the adequacy and execution of healthcare facilities’ emergency plans.

Progress in Addressing the Challenge
CMS developed guidance to help healthcare facilities improve planning and preparing for disasters, improve access to medical care, and meet medical surge needs during disasters. In 2016, CMS finalized a rule to establish new national emergency preparedness requirements that apply to all facilities receiving Medicare or Medicaid reimbursement. In 2017, CMS issued guidelines for providers and surveyors when assessing compliance with Federal regulations for long-term-care facility emergency
planning and training. As of September 2018, CMS has reported surveying about 75 percent of facilities, and anticipates survey completion by February 2019.

The Office of the Assistant Secretary for Preparedness and Response (ASPR) continues to provide technical assistance and guidance to healthcare providers, emergency managers, and other public health emergency preparedness stakeholders on topics including medical surge and improving collaboration during and after disasters. Additionally, ASPR has developed data tools to assist entities with rapidly identifying resource availability (e.g., electricity and beds) and at-risk populations that need assistance during an emergency. ASPR is also integrating Federal, State, local public health, and medical assets on the ground and building regional capability to fight highly infectious and other disease threats through regular training, exercises, and ensuring that equipment and organization of medical components are updated.

**What Needs To Be Done**

- HHS should take steps to improve coordination within the public health and human services infrastructure. For example, CMS needs to ensure that all applicable providers are effectively implementing the emergency preparedness requirements.
- CMS needs to ensure that all surveyors are effectively assessing providers’ compliance with these requirements. OIG will continue to monitor these requirements.
- ASPR should continue to improve the use and collection of data to access real-time information about emerging threats and to rapidly respond to emergencies to ensure they meet the health and human service needs of individuals.
- ASPR should continue to build regional surge capacity through formula-based cooperative agreements, Regional Disaster Health Response System pilots, and support programs related to healthcare preparedness, response, and recovery.

**Ensuring effective use and oversight of funding**

**Key Components of the Challenge**

HHS awards grant funds across Federal, State and local entities to strengthen emergency preparedness. HHS, States, and other grantees also receive supplemental appropriations to respond to emergencies. In 2017, HHS received almost $6 billion in supplemental funding for preparedness and response efforts for the hurricanes impacting Puerto Rico, the Virgin Islands, and the southern U.S. Funds awarded during emergencies are often susceptible to fraud and misuse by grantees.

HHS must also see that proper grant mechanisms are in place to ensure effective response coordination with domestic and international partners. For example, OIG found deficiencies in CDC’s grant award process to award funds for international Ebola preparedness and response activities. States also reported wanting more direction from ACF on allowable activities and reporting requirements for Superstorm Sandy block grants. Uncertainty about allowable expenses may have hindered some States’ use of funds for relief efforts. Additionally, OIG also found internal control weaknesses in audits of foreign grantees receiving President’s Emergency Plan for AIDS Relief funds (see TMC #7 for more information on challenges specific to HHS grants).

**Progress in Addressing the Challenge**

HHS has made efforts to assess grant program performance and improve grant oversight by identifying potential fraud, waste, and abuse. For instance, OIG found that HRSA complied with Federal and HHS
grant policies when awarding funding to health centers and other entities to expand access and delivery of healthcare services to respond to the spread of the Zika Virus in Puerto Rico and other U.S. territories from October 1, 2016, through March 15, 2017. Additionally, ACF is developing administrative guidance on lessons learned to use if additional supplemental disaster funds are appropriated to the agency under the Social Services Block Grant authority.

**What Needs To Be Done**

- HHS needs to improve its oversight of funds awarded to grantees for emergency response and recovery activities to ensure that grant funds are being used efficiently, effectively, and for their intended purposes.
- HHS agencies must provide appropriate guidance to its grantees about when the use and expiration of supplemental disaster relief funds and what documentation is needed to ensure program integrity.

**Ensuring effective and timely responses to infectious disease threats**

**Key Components of the Challenge**

The spread of infectious diseases, like Ebola and Zika, is an ongoing challenge and demonstrates the need for the Department to rapidly detect and diagnose infectious diseases and assess threats. HHS needs to ensure its ability to readily develop, distribute, and administer medical countermeasures (MCMs) (i.e., vaccines, therapeutics, and diagnostics) to effectively prevent and treat infectious diseases. OIG identified systemic issues that may prevent CDC from ensuring inventory in the Strategic National Stockpile (SNS)—a repository of MCMs.

Additionally, HHS needs to enhance State and local preparedness for influenza pandemics. OIG found that States and localities need to improve planning and preparedness in areas including medical surge and vaccine and antiviral drug distribution and dispensing. For example, during the Ebola crisis, many hospitals reported that they were unprepared to receive cases and experienced challenges, such as difficulty using Federal guidance, to sustain preparedness.

**Progress in Addressing the Challenge**

HHS continues to make significant investments to develop MCMs to protect against emerging infectious diseases and other threats. For example, ASPR is sustaining efforts to build domestic manufacturing infrastructure and a robust vaccine stockpile for pandemic influenza. As of September 2018, ASPR’s Biomedical Advanced Research and Development Authority (BARDA) supported an MCM enterprise that included 42 FDA approvals of 38 medical products and technologies. BARDA’s Division of Research, Innovation, and Ventures (DRIVe) program also supports transformational technologies to identify diseases earlier and address cross cutting health security threats.

HHS is also enhancing preparedness for future infectious disease threats. In April 2018, HHS executed its largest patient movement exercise, with more than 50 organizations (including Federal, State, and local agencies) participating, to test the nation-wide ability to move patients with highly infectious diseases safely and securely to regional treatment centers. OIG’s ongoing work has also identified improvements in hospital preparedness for responding to emerging infectious diseases. For instance, following the Ebola crisis, hospitals reported taking actions such as revising infectious disease and emergency plans, conducting additional staff training and exercises, and participating in healthcare coalitions. In response to OIG’s work, CMS is updating its State Operations Manual to include emerging
infectious diseases in hospital emergency planning. Additionally, ASPR is building on its successes using a regional response model during the Ebola response by developing a Regional Disaster Health Response System to surge medical response during disasters and emergencies.

**What Needs To Be Done**

- HHS agencies should take steps to improve collaboration and coordination of guidance to help healthcare facilities sustain preparedness for emerging infectious disease threats.
- CMS should monitor enforcement of its emergency preparedness requirements to ensure that emerging infectious diseases are included in hospital preparation.
- ASPR should continue efforts to expand the portfolio of emerging infectious disease MCMs under development.
- HHS should improve SNS coordination and readiness to ensure that inventory is readily deployable in a public health emergency. To that end, plans are underway for ASPR to assume operational control of the SNS to streamline MCM development and procurement and improve the speed and effectiveness of emergency response capabilities.

**Key OIG resources**

- *Examining Federal Efforts to Ensure Quality of Care and Resident Safety in Nursing Homes (OIG Testimony),* September 2018.
2018
Top Management and Performance Challenges